ФОСФАТНЫЕ ПРОИЗВОДНЫЕ ФТОРОКСИНДОЛОВ И СПОСОБ ЛЕЧЕНИЯ С ИХ ИСПОЛЬЗОВАНИЕМ

Изобретение относится к группе новых соединений формулы (I) где волнообразная связь обозначает рацемат, (R)-энантиомер или (S)-энантиомер; А представляет собой прямую связь или (С=O); В представляет собой прямую связь, кислород или азот; m имеет значение 0 или 1; n имеет значение 1, 2 или 3; R1 и R2 каждый независимо является водородом или C1-6алкилом, и когда R1 представляет собой водород, R2 может также быть P(O)OR5OR6; R3 и R4 каждый независимо является водородом или C1-4 алкилом; R5 и R6 каждый независимо является водородом, или к их нетоксичным фармацевтически приемлемым солям или сольватам. Изобретение также относится к способу лечения заболеваний, чувствительных к раскрытию активируемых кальцием калиевых каналов. Технический результат - получение новых биологически активных соединений и способ лечения заболеваний, чувствительных к раскрытию активируемых кальцием калиевых каналов большой проводимости у млекопитающего. 2 н. и 7 з.п. ф-лы, 1 табл.

ИОННАЯ ЖИДКОСТЬ, СОДЕРЖАЩАЯ ИОН ФОСФОНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

Настоящее изобретение относится к ионным жидкостям на основе катиона, представленного формулой (I): ! ! где замещающие группы R1-R9 выбраны из водорода, алкила; любой атом углерода в R1-R9 может быть замещен группой -O-, -С(O)-, -С(O)O-, -S-, -S(O)-, -SO2- или -SO3-; Х представляет собой S, О или С; R8 и R9 существуют, только когда Х представляет собой углерод; анион выбран из групп [RSO3]-, [RfSO3]-, [(RfSO2)2N]-, [(FSO2)3C]-, [RCH2OSO3]-, [RC(O)O]-, [RfC(O)O]-, [CCl3C(O)O]-, [(CN)3C]-, [(CN)2CR]-, [(RO(O)C)2CR]-, [B(OR)4]-, [N(CF3)2]-, [N(CN)2]-, [AlCl4]-, PF6 -, BF4 -, SO4 2-, HSO4 -, ! NO3 -; где R представляет собой водород, галоген, алкил, алкенил, алкинил, циклоалкил, Rf представляет собой фторсодержащую замещающую группу. Технический результат - получение новых ионных жидкостей с улучшенными электрохимическими свойствами. 14 з.п.ф-лы, 2 ил.

СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ СО СТАРЕНИЕМ

Настоящее изобретение относится к соединению для устранения стареющих клеток, лечения и предупреждения диабета и ожирения формулы Ia:,где Z представляет собой линейный Салкилен, где необязательно одна пара атомов углерода в углеводородной цепи может быть заменена одним триазолом, и/или один атом углерода в углеводородной цепи может быть заменен группой NH; где углеводородная цепь не замещена или замещена =О; каждый из R1, R2, R3 независимо выбран из Cалкила, Cарила, Cарил-Cалкила, Cциклоалкила, где каждый из R1, R2, R3 необязательно и независимо может быть замещен одним или более Cалкокси; Xпредставляет собой фармацевтически приемлемый анион; где перекрещенная двойная связь в общей формуле Ia указывает на то, что двойная связь может иметь E- и/или Z-конфигурацию; при условии, что все из R1, R2 и R3 не представляют собой одновременно незамещенные фенилы; или его фармацевтически приемлемой соли. 2 н. и 6 з.п. ф-лы, 26 пр., 10 табл.

СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ, СОЕДИНЕНИЯ, КОМПЛЕКСНЫЙ МЕТАЛЛООРГАНИЧЕСКИЙ КАТАЛИЗАТОР

... 1. Способ получения соединения формулы (I)в которой R1 и R2 могут быть одинаковыми или различными и по отдельности представляют собой замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси, алкиламино-, циклоалкиламино, ариламино, металлоценильной группы;R3, R4, R5, R6 могут быть одинаковыми или различными и по отдельности представляют собой атом водорода либо замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси-, алкиламино-, циклоалкиламино-, ариламиногруппы;Е представляет собой замещенную или незамещенную группу, выбранную из PR7R8, P(BH)R7R8, -CH-PR7R8, -CH-P(BH)R7R8, -BR9R10, -CR11R12OH, -COR11, -SiR11R12R13; -SiR11R12-CH-PR7R8;где R7 и R8 могут быть одинаковыми или различными и по отдельности представляют собой водород, замещенную или незамещенную группу, выбранную из алкильной, циклоалкильной, арильной, алкилокси-, циклоалкилокси-, арилокси, ...

СПОСОБ ПОЛУЧЕНИЯ БИС(ПЕРФТОРАЛКИЛ)ФОСФИНОВЫХ КИСЛОТ И ИХ СОЛЕЙ

... 1. Способ получения бис(перфторалкил)фосфиновых кислот или их солей, который включает, по крайне мере, следующие стадии способа: а) взаимодействие, по крайне мере, одного дифтортрис(перфторалкил)фосфорана или, по крайне мере, одного трифторбис(перфторалкил)фосфорана с фтороводородом в пригодной реакционной среде, б) нагревание полученной на стадии а) реакционной смеси. 2. Способ получения бис(перфторалкил)фосфиновых кислот или их солей в соответствии с п.1, отличающийся тем, что соли получают последующей нейтрализацией. 3. Способ в соответствии с п.1, отличающийся тем, что используемый дифтортрис(перфторалкил)фосфоран или трифторбис(перфторалкил)фосфоран представляет собой соединение общей формулы I где 1≤n≤8, предпочтительно 1≤n≤4, и m в каждом случае=2 или 3. 4. Способ по п.1, отличающийся тем, что используемый дифтортрис(перфторалкил)фосфоран представляет собой соединение выбираемое из группы, которая включает дифтортрис(пентафторэтил)фосфоран, дифтортрис(н-нонафторбутил)фосфоран и дифтортрис ...

Способ огнезащитной отделки волокнистого материала

NEUE 11-DEOXY-PROSTAGLANDINE E, F TIEF ALPHA UND F TIEF BETA

HERSTELLUNG VON ONIUMHYDROXIDEN IN ELEKTROCHEMISCHEN ZELLEN

Improvements relating to quaternary phosphonium compounds and their use

The invention comprises quaternary phosphonium compounds of the general formula wherein A represents a halogen-substituted radical of the phenyl, diphenylyl or phenoxyphenyl series, Y represents an oxygen or sulphur atom, Z represents a low molecular alkylene radical (which means one containing 1 to 3 carbon atoms: it can be represented by -CH2-, -CH2-CH2-, -CH2-CH2-CH2-or -CH2-CH-CH3), n represents 0 or 1 and X represents halogen. Such compounds are obtained by reacting halogen methyl ethers of the general formula A-(Y-Z)n-CH2-O-CH2-X with triphenyl phosphine. As a modification a halomethyl ether of the general formula A-O-Z-CH2-O-CH2-X wherein A represents a monophenyl, diphenylyl or a phenoxyphenyl radical which contains no halogen or at most two halogen atoms, Z represents a low molecular alkylene radical and X represents halogen, is reacted with triphenyl phosphine to produce a quaternary phosphonium compound which is then treated with a halogenating agent.

Production of mono-and poly-unsaturated aldehydes or their functional derivatives

Mono- or poly-unsaturated aldehydes or their functional derivatives are prepared by reacting an acetal, hemiacetal, mercaptal, aminal, acylal, oxime, hydrazone, semicarbazone or Schiff's base derivative prepared from phosphonium salts having the formula in which Ar denotes an aryl radical optionally substituted by alkyl or alkoxy groups, X is an anion, and n is an integer from 0 to 6, with a proton acceptor to convert the compounds into their ylids which are simultaneously or subsequently reacted with aldehydes or ketones by a Wittig reaction. The aldehyde derivatives so obtained may be hydrolysed to the corresponding aldehydes. Examples of phosphonium salts of Formula III mentioned are triphenylformylmethyl phosphonium chloride, triphenyl-b -formylcrotyl phosphonium chloride, triphenyl-b -formylcrotyl phosphonium bromide, triphenyl-a - formylcrotyl phosphonium chloride, triphenyl - 5 - formyl - 5 - methylpentadiene - (2,4)-yl phosphonium chloride, and triphenyl-7-formyl ...

Organometallic electrolytes for the electrode position of various metals

In the electrolytic deposition of metals from organo-metal complexes, a suitable electrolyte for depositing Al, Zn, Ga, and In, is made by adding a compound of formula MeX1mRn to a compound of formula [R1R2R3R4Y]X2, where Me i Al, Zn, Ga, In, X1 and X2 are halogen, sulphate, cyanide, oxide or trifluoro methyl, R is alkyl of 1 - 6 C atoms, Y is N, P, Te, or As, and R1R2R3R4 of which one or more is phenyl, benzyl, aplobenzyl or strongly branched hydrocarbon of 3 to 12 C atoms and the remainder is alkyl of 1 - 4 C atoms. 1 to 2 mols of the metal complex is added to 1 mol of the second compound with solvents e.g. aromatic hydrocarbons or ethers if necessary. A typical product is [(CH3)3 (C6H5 CH2)N]F.2Al(C2H5)3, and is not spontaneously ignitable, or fuming in air. A table of examples of metal complexes is given with their conductivities. In examples, the aluminium complex diluted with toluene is used to plate copper, brass, nickel, or a molybdenum wafer at 2-5-3V with stirring. If toluene ...

NOVEL BEZ[e]INDENE AND PHENANTHRENE DERIVATIVES

... 1298219 Steroid precursors F HOFFMANNLA ROCHE & CO AG 20 Nov 1969 [22 Nov 1968] 28140/71 Divided out of 1298214 Heading C2C The invention comprises d, I and dl compounds of Formula I wherein m is 1 or 2; R1 is C 1-5 primary alkyl; R2 is lower alkyl; and Z4 is di- (lower alkoxy) -methylene, phenylenedioxymethylene, a methylene group substituted by a divalent -ORO-, -ORS-, -SRS- or -ORNH- group (where R is lower alkylene), or is a group of formula wherein R6 is H or lower aliphatic or alicyclic hydrocarbyl and R7 is H, lower alkyl, (lower alkoxy)-(lower alkyl), phenyl-(lower alkyl) or tetrahydropyran-2-yl. The term "lower" means having up to 8 carbon atoms. Compounds I are prepared from compounds II [wherein R2 and R3 are identical lower alkyl groups or one of R2 and R3 is H and the other is lower alkyl, and Z2 is as defined for Z4 above or is #- (lower acyloxy)- or -R6-methylene (where ...

PROCESS FOR THE MANUFACTURE OF PHOSPHORUS-CONTAINING CONDEN SATION PRODUCTS, THE PRODUCTS AND THEIR USE AS FLAMEPROOFING AGENTS

... 1390263 Phosphorus-containing condensation polymers CIBA-GEIGY AG 5 Sept 1972 [10 Sept 1971] 41097/72 Heading C3R [Also in Division D1] Condensation products are obtained by condensing 1 mol. of a tetrakis-(hydroxymethyl)- phosphonium compound with 0À02 to 0À2 mol. of an optionally methylolated dicyandiamide at 40 degrees to 120 degrees optionally in the presence of formaldehyde or a formaldehydedonating agent and optionally in an inert organic solvent. The condensation optionally may be continued at 100‹ to 150‹ C. and free hydroxyl groups may be etherified. Organic fibre materials may be flameproofed by applying to them aqueous compositions of the condensation products together with polyfunctional epoxides or nitrogen compounds, and curing by heating the materials either when dry or while still moist or by contacting them with ammonia. In examples condensation products are obtained by reacting tetrakis-(hydroxymethyl)-phosphonium chloride and hydroxide with dicyandiamide and with the ...

Ionic liquids

A PROCESS FOR THE MANUFACTURE OF 19-NORSTEROIDS

... 1298214 19-Norsteroid synthesis F HOFF. MANN-LA ROCHE & CO AG 20 Nov 1969 [22 Nov 1968] 56793/69 Headings C2C and C2U The invention comprises the preparation of d-, l- and dl-19-norsteroids of partial Formula (I) by three routes from d-, l- and dl-19-isoxazolyl-de-A-steroids of partial Formula (II) wherein R2 and R3 are identical C 1-8 alkyl groups or one of R2 and R3 is H and the other is C 1-8 alkyl, and R4 is H or a C 1-7 alkyl group having one CH 2 group less than R2 or R3. Route 1 comprises hydrogenation of (II) to yield a 4-azagon-2-ene of partial Formula (A) treatment of which with an anhydrous strong base yields a 4-azagona-2,5(10)-diene of partial Formula (D) hydrolysis of which yields a de-A-steroid of partial Formula (C) cyclization of which yields (I). The specific examples do not illustrate this route. Route 2 comprises hydrogenation of (II) to yield (A) as in route 1, treatment of (A) with an aqueous strong base ...

Stable, water-containing solutions of azo-dyestuffs

Stable, water-containing solutions of normally insoluble or difficultly soluble azo dyestuffs contain (a) an azo dye containing at least one weakly acid group, i.e. a hydrogen atom capable of being substituted, and (b) a cationic surface active agent. The solutions may also contain a strongly basic agent and/or an organic solvent. The quantity of surfactant (b) required may be 2-40, preferably 5-20 times by weight the weight of dyestuff used. The dye may first be dissolved in a strong aqueous solution of surfactant (b) and then the base and organic solvent may be added if required or alternatively the dye may first be dissolved in the base and organic solvent to which solution the surfactant is added. A very large number of suitable cationic surfactants (b) are specified which fall into the following classes: fatty amines and derivatives and oxyethylation products thereof, preferably in the form of their salts, especially compounds of the formula where R is an organic ...

NOVEL BEZ[e]INDENE AND PHENANTHRENE DERIVATIVES

... 1298218 Steroid precursors F HOFFMANNLA ROCHE & CO AG 20 Nov 1969 [22 Nov 1968] 28139/71 Divided out of 1298214 Heading C2C The invention comprises d, I and dl compounds of Formulµ Ia and Ib wherein m is 1 or 2; R1 is C 1-5 primary alkyl; R2 and R3 are identical lower alkyl groups or one of R2 and R3 is H and the other is lower alkyl; Z1 is carbonyl, (lower alkylenedioxy)- methylene, di - (lower alkoxy) - methylene, phenylenedioxy-methylene or a group of formula where R5 is H, lower alkyl, (lower alkoxy)- (lower alkyl), phenyl-(lower alkyl), tetrahydropyran-2-yl or lower acyl and R6 is H or lower aliphatic or alicyclic hydrocarbyl; and Z2 is di- (lower alkoxy) - methylene, phenylenedioxymethylene, a methylene group substituted by a divalent -ORO-, -ORS-, -SRS- or -ORNH- group (where R is lower alkylene), or is a group of Formula III defined above. The term " lower" means having up to 8 carbon atoms. Compounds ...

New metal salts of mixed acids dithiocarbamic, their preparation and their application like fungicides.

NEW COMPOSITIONS FOR THE STABILIZATION OF NUCLEIC ACIDS IN BIOLOGICAL MATERIALS

VERFAHREN ZUR HERSTELLUNG VON NEUEN POLYENVERBINDUNGEN

PROCEDURE FOR THE PRODUCTION OF ORGANOPHOSPHINEN

PROCEDURE FOR the PRODUCTION of a NEW ONE 3-INDENYLESSIGSAURE

CLEANING AGENT

Thermoplastic molding materials from polypropylene and low pressure PL

PROCEDURE FOR THE PRODUCTION OF PERFLUORALKANSULFONSÄUREESTERN AND THEIR SALTS

PROCEDURE FOR the PRODUCTION of the NEW ONES 5-FLUOR-2-METHYL-1 (4 ' - METHYLSULFINYLBENZYLIDEN) - 3-INDENYL-ESSIGSAURE

PRODUCTION OF ONIUMHYDROXIDEN IN ELECTRO-CHEMICAL CELLS

Procedure for the production of new quaternären ammonium and Phosphonium boron complexes

ANTIOXIDANTIEN WITH SPECIFIC EFFECT ON MITOCHONDRIEN

PROCEDURE FOR THE PRODUCTION OF NEW POLYENVERBINDUNGEN

Procedure for the production of new Isoxazolderivate

VERFAHREN ZUR HERSTELLUNG DER NEUEN 5-FLUOR-2-METHYL-1-(4'-METHYLSULFINYLBENZYLIDEN)-3-INDENYL-ESSIGSAURE

Procedure for the production of new Isoxazolderivate

Procedure for the production of new Isoxazolderivate

Procedure for the production of new Isoxazolderivaten, their Ketalen and salts

Procedure for the soft handy making of synthetic materials

PHOSPHORUS-CONTAINING CONDENSATION PRODUCTS

PHOSPHATE PRODRUGS OF FLUOROOXINDOLES

PREPARATION METHOD OF VALIENAMINE FROM ACARBOSE AND/OR ACARBOSE DERIVATIVES USING TRIFLUOROACETIC ACID

DETERGENT COMPOSITION HAVING ENHANCED PARTICULATE SOIL REMOVAL PERFORMANCE

Use of compositions consisting of cationic compounds and proton donors for stabilising and/or isolating nucleic acids in or from micro-organisms such as prokaryots, fungi, protozoa or algae

11-DEOXY PROSTAGLANDINS

Methods for producing or purifying onium hydroxides by means of electrodialysis

Preparation of onium hydroxides in an electrochemical cell

Mitochondrially targeted antioxidants

PROCESS FOR THE PREPARATION OF BENZINDENES

USE OF COMPOSITIONS CONSISTING OF CATIONIC COMPOUNDS AND PROTON DONORS FOR STABILISING AND/OR ISOLATING NUCLEIC ACIDS IN OR FROM MICRO-ORGANISMSSUCH AS PROKARYOTS, FUNGI, PROTOZOAOR ALGAE

The invention relates to the use of compositions for isolating and/or stabilising nucleic acids in or from micro-organisms such as prokaryots, fungi, protozoa or algae. The composition comprises a cationic compound of general formula Y+R1R2R3R4 X' as an essential constituent; wherein Y can represent nitrogen or phosphorus; R1, R2, R3 and R4 can independently represent an unbranched or branched C1-C20 alkyl radical and/or a C6-C20 aryl radical and a C6-C26 aralkyl radical; and X' can represent an anion pertaining to an inorganic or organic, monobasic or polybasic acid.

SALTS COMPRISING CYANOBORATE ANIONS

Disclosed are a method for producing alkali metal cyanoborates, the further processing thereof into salts comprising cyanoborate anions and organic cations, said salts, and the use thereof as ionic liquids.

PEROXIDE COMPOSITIONS BASED ON TUNGSTEN AND PHOSPHORUS OR ARSENIC

This invention relates to compositions of formula (I): Q3XW4O24-2n (I) wherein: Q represents a cation of an "onium" salt; X is either a P or As atom, while n is a number chosen between 0;1 and 2. These compositions can be prepared by in reacting an oxygenated tungsten (VI) derivative, an oxygenated P (V) or As (V) derivative and hydrogen peroxide, in an aqueous acid phase, with a "onium" salt or a precursor thereof possibly contained in an organic phase unmixable with the aqueous phase, at substantially room temperature. The oxygenated compounds of W (VI), P (V) or As (V) may possibly be prepared 'in situ' under the conditions of the reaction. The compositions (I), which show up as solids or as viscous oils, find their use as oxidizing agents in general in oxidation processes, and especially as epoxydation catalysts for olefinic compounds, both in a homogeneous phase as well as in a heterogeneous phase, and preferably according to the phase-transfer technique, in the presence of oxidizing ...

CLAY-CATION COMPLEXES

An organophilic clay gellant comprising the reaction product of an organic cationic compound and a smectite-type clay having a cation exchange capacity of at least 75 milliequivalents per 100 grams of said clay, wherein said organic cationic compound contains (a) a first member selected from the group consisting of a .beta., .gamma.-unsaturated alkyl group, and a hydroxyalkyl group having 2 to 6 carbon atoms, and mixtures thereof, (b) a second member comprising a long chain alkyl group having 12 to 60 carbon atoms and (c) a third and fourth alkyl member.

SALTS COMPRISING CYANOBORATE ANIONS

Disclosed are a method for producing alkali metal cyanoborates, the further processing thereof into salts comprising cyanoborate anions and organic cations, said salts, and the use thereof as ionic liquids.

PROCESS FOR PREPARING HYDROCARBON ACID ESTERS

PROCESS FOR THE MANUFACTURE OF PHOSPHORUS-CONTAINING CONDENSATION PRODUCTS, THE PRODUCTS THEIR USE AS FLAMEPROOFING AGENTS

METHOD FOR PRODUCING PERFLUOROALKANE SULFONIC ACID ESTERS AND THE SALTS THEREOF

The invention relates to a method for producing perfluoroalkane sulfonic acid esters and their subsequent conversion into salts, in addition to the use of the produced compounds in electrolytes and batteries, capacitors, supercapacitors and galvanic cells.

TRIPHENYLPHOSPHONIUM SALT COMPOUNDS, PREPARATION METHOD AND USE THEREOF

Disclosed are a quaternary triphenylphosphonium salt compound, a preparation method therefor, and the uses thereof. The structure of the quaternary compound is as shown in formula I. The preparation method comprises carrying out a nucleophilic reaction of the compound shown of formula VII and triphenylphosphine in an organic solvent with or without a catalyst to obtain the compound as shown in formula I. The compound as shown in formula I can be used for preventing and treating diseases caused by a plurality of germs such as oomycetes, basidiomycetes, ascomycetes and semi-known fungi on a variety of plants. Excellent results have been obtained in powdery mildew, corn rust, watermelon anthracnose and the like, and a good control effect can be ensured at low concentrations.

INDENYL ACETIC ACIDS AND PROCESSES FOR PREPARING SAME

ALKYLATION PROCESS USING PHOSPHONIUM-BASED IONIC LIQUIDS

A process for making an alkylate is presented. The process includes mixing an isoparaffin stream with an olefin stream in an alkylation reactor. The alkylation reactor includes a catalyst for performing the reaction. The catalyst is an ionic liquid that is a quaternary phosphonium based ionic liquid, and the reaction is performed at or near ambient temperatures.

Indenylacetic acid derivs - useful as antiinflammatory agents

Anti-inflammatory indenylacetic acid derivatives. Compds. of formula:- (where Ar = aryl or heteroaryl; R1 = H, 1-4C alkyl, 1-4C haloalkyl; R2 = H or 1-6C alkyl; R3, R4, R5, R6 = H, halo, alkyl, acyloxy, alkoxy, nitro, amino, acylamino, alkylamino, dialkylamino, dialkylaminoalkyl, sulphamyl, alkylthio, mercapto, hydroxy, hydroxyalkyl, alkylsulphonyl, cyano, carboxyl, carbalkoxy, carbamido, haloalkyl, cycloalkyl, cycloalkoxy where all alkyl, acyloxy and alkoxy groups have 1-6C; R7 = 1-6C alkylsulphonyl, 1-6C alkylsulphonyl; R8 = H, halo 1-6C alkoxy, 1-6C haloalkyl; M = hydroxy, opt. substd. alkoxy, amino, alkylamino, dialkylamino, N-morpholino, hydroxyalkylamino, polyhydroxyalkylamino, dialkylaminoalkylamino, aminoalkylamino or a group OMe where Me is a cation, where all alkyl and alkoxy gps. are 1-6C. The compounds may be as or transisomers or a racemate or optically active form) also exhibit analgesic and antipyretic activity.

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung.

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung.

Verfahren zur Herstellung von Yliden des Phosphors

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung.

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung.

Verfahren zur Herstellung einer quaternären Phosphoniumverbindung.

Verfahren zum Färben oder Bedrucken von Textil-Fasermaterialien

Verfahren zur Reindarstellung von Verbindungen der Carotinoid- und Vitamin-A-Reihe

Verfahren zur Herstellung von Spirilloxanthin

Verfahren zur Herstellung von B-Jonylidenäthyltriaryl-phosphoniumhalogeniden

Verfahren zur Darstellung von Oniumfluoriden

Verfahren zur Herstellung von metallorganischen Komplexverbindungen

Preparation of b-carotene and intermediates thereof

The preparation of cis-beta-carotene by reacting (A) a phosphonium salt prepared from mother liquors which are one of (1) those containing uncrystallizable C20 material remaining after the synthesis of crystallisable vitamin A alcohol; (2) those containing uncrystallizable C20 to C36 material remaining after the synthesis of crystallisable alkyl esters of vitamin A alcohol; and (3) those containing uncrystallizable C20 material remaining after the synthesis of crystallisable C20 intermediates convertible to vitamin A alcohol or esters thereof; with (B) vitamin A aldehydes prepared from any of the foregoing mother liquors, in the presence of an inert solvent and a proton acceptor. The cis-beta-carotene may, if desired, be isomerized by heating to 50 deg.-100 deg.C in an inert organic solvent to form all -trans-beta-carotene.

Metériel sensible aux radiations

Preparation of b-carotene and intermediates thereof

The preparation of cis-beta-carotene by reacting (A) a phosphonium salt prepared from mother liquors which are one of (1) those containing uncrystallizable C20 material remaining after the synthesis of crystallisable vitamin A alcohol; (2) those containing uncrystallizable C20 to C36 material remaining after the synthesis of crystallisable alkyl esters of vitamin A alcohol; and (3) those containing uncrystallizable C20 material remaining after the synthesis of crystallisable C20 intermediates convertible to vitamin A alcohol or esters thereof; with (B) vitamin A aldehydes prepared from any of the foregoing mother liquors, in the presence of an inert solvent and a proton acceptor. The cis-beta-carotene may, if desired, be isomerized by heating to 50 deg.-100 deg.C in an inert organic solvent to form all -trans-beta-carotene.

Verfahren zur Herstellung von neuen Bis-stilbenverbindungen

Verfahren zur Herstellung von (cis-1,2-Epoxypropyl)- phosphonsäurederivaten

Bis-stilbene compds for use as optical brighteners

Fluorescent bis-stilbene compds. for use as optical brighteners have formula (I). R1 - CH = CH - X - CH = CH - R2 X = a diphenyl group linked at the 4 and 4' positions with the CH group; and R1 and R2 = each monocyclic benzene groups, diphenyl groups or naphthalene groups; and at least one of the rings X, R1 and R2 is substd. by sulphonic acid, sulphone, carboxylic acid, nitrile, hydroxyl, mercapto or methyl. (I) are useful optical bighteners for treating org. materials, including synthetic polymers and fibres.

Verfahren zur Herstellung von neuen Isoxazolderivaten

Verfahren zur Herstellung von neuen Isoxazolderivaten

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILFASERMISCHUNGEN AUS POLYESTER-CELLULOSE.

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILMATERIALIEN.

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILMATERIALIEN.

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILMATERIALIEN.

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILMATERIALIEN.

VERFAHREN ZUR HERSTELLUNG VON (CIS-1,2-EPOXY-PROPYL)-PHOSPHONSAEURE UND DEREN ESTERN, SALZEN UND AMIDEN.

Verfahren zur flammbeständigen Ausrüstung von Textilmaterial

Indenylacetic acid derivs - useful as antiinflammatory agents

Anti-inflammatory indenylacetic acid derivatives. Compds. of formula:- (where Ar = aryl or heteroaryl; R1 = H, 1-4C alkyl, 1-4C haloalkyl; R2 = H or 1-6C alkyl; R3, R4, R5, R6 = H, halo, alkyl, acyloxy, alkoxy, nitro, amino, acylamino, alkylamino, dialkylamino, dialkylaminoalkyl, sulphamyl, alkylthio, mercapto, hydroxy, hydroxyalkyl, alkylsulphonyl, cyano, carboxyl, carbalkoxy, carbamido, haloalkyl, cycloalkyl, cycloalkoxy where all alkyl, acyloxy and alkoxy groups have 1-6C; R7 = 1-6C alkylsulphonyl, 1-6C alkylsulphonyl; R8 = H, halo 1-6C alkoxy, 1-6C haloalkyl; M = hydroxy, opt. substd. alkoxy, amino, alkylamino, dialkylamino, N-morpholino, hydroxyalkylamino, polyhydroxyalkylamino, dialkylaminoalkylamino, aminoalkylamino or a group OMe where Me is a cation, where all alkyl and alkoxy gps. are 1-6C. The compounds may be as or transisomers or a racemate or optically active form) also exhibit analgesic and antipyretic activity.

Prepg. fluorescent bis-stilbene cpds. - for use as optical brighteners for organic materials

Title cpds. of formula (I): (where R3 is diphenylyl or the gp. (a): R4 is phenyl, diphenyl, alpha- or beta-naphthyl or the gp. (a) V1', V2' and V3' replacing V1, V2 and V3, and in which V1 and V2' are indep. sulpho gps. together with their salts, esters, amides and halides or carboxyl gps. together with their salts, esters and amides, or they are CN, Me, OH or sulphonyl; V2 and V2' are indep. H, 1-18C alkyl, 1-12C alkoxy, halogen, or sulpho gps. together with their salts, esters or amides; V3 and V3' are indep. H or 1-4C alkyl; W1 is sulpho together with the salts, esters or amides, 1-4C alkyl or alkoxy, carboxyl together with the salts, esters, or amides, CN or halogen; W1 or V1 and/or V1' may also be H; when W1 differs from H, R3 and/or R4 are diphenylyl) are prepd. by reacting 1 mol. of (II): with 1 mol. of R3-CHO and 1 mol. of R4-CHO, or 1 mol. of (II) where CHO-replaces Z3 is reacted with 1 mol. of R3-Z3 and 1 mol. of Z3-R4 (where Z3 is -CH2-PO(OR)2, -CH2(PO)ROR or -CH=P(R)3, in which ...

VERWENDUNG WASSERLOESLICHER, PHOSPHORHALTIGER KONDENSATIONSPRODUKTE ZUSAMMEN MIT POLYFUNKTIONELLEN VERBINDUNGEN ZUM FLAMMFESTMACHEN VON TEXTILFASERMISCHUNGEN AUS POLYESTER-CELLULOSE.

Process for the preparation of perfluoroalkylcyano- or perfluoroalkylcyanofluoroborates

The invention relates to a process for the preparation of salts having perfluoroalkyltricyano- or perfluoroalkylcyanofluoroborate anions, ((per)fluoro)phenyltricyano- or ((per)fluoro)phenylcyanofluoroborate anions, phenyltricyanoborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms or phenylcyanofluoroborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms, by reaction of alkali metal trifluoroperfluoroalkylborate with trialkylsilyl cyanide and a subsequent salt-exchange reaction or by direct reaction of an organic trifluoroperfluoroalkyl borate with trialkylsilyl cyanide.

Mitochondrial Compositions and Uses Thereof

The present invention provides a compound of Formula 1a, wherein R 1 is H or phosphate and the double bond is between N′ and C′ or between N 2 and C 1 ; R 2 is a mitochondrial targeting moiety; R 3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R 4 is H or an alkyl, aryl, or heteroaryl group; and R 5 is alkyl, aryl, or heteroaryl; or N′ C′, and N 3 together form a heterocyclic ring containing at least 5 atoms, wherein N 1 , N 3 , and R 1 -R 5 are as defined above, or N 3 and R 5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.

Phosphonium-based ionic liquids and their use in the capture of polluting gases

An ionic liquid composition having the following chemical structural formula: wherein R 1 , R 2 , R 3 , and R 4 are independently selected from hydrocarbon groups containing at least 1 and up to 20 carbon atoms, and X − is a cyclic anion that possesses a negatively-charged group reactive with a gaseous electrophilic species, particularly carbon dioxide or sulfur dioxide. Methods for capturing a gaseous electrophilic species, such as CO 2 or SO 2 , by contacting the gaseous electrophilic species with an ionic liquid according to Formula (1) are also described.

PROCESS FOR THE PREPARATION OF OXOVINYLIONOL AND ITS O-PROTECTED DERIVATIVES

The present invention relates to the preparation of oxovinylionol and its O-protected derivatives of the formula I 123.-. (canceled)25. The process according to claim 24 , wherein the oxidant comprises an organic hydroperoxide which is selected from among alkyl hydroperoxides and arylalkyl hydroperoxides.26. The process according to claim 25 , wherein the organic hydroperoxide is selected from among tertiary C-C-alkyl hydroperoxides.27. The process according to claim 24 , wherein the oxidant is employed in an amount of from 1 to 10 mol per mole of the compound of the formula II.28. The process according to claim 24 , wherein the transition metal is employed in the form of a transition metal compound.29. The process according to claim 24 , wherein the transition metal is selected from among Cu claim 24 , Co claim 24 , Fe and Mn and their mixtures.30. The process according to claim 29 , wherein the transition metal is employed in the form of at least one compound which is selected from among CuCl claim 29 , CuCl claim 29 , CuI claim 29 , CoCl claim 29 , Cu(II)oxalate claim 29 , Co(II) salts of organic monocarboxylic acids claim 29 , such as Co(acetate) claim 29 , Co(2-ethylhexanoate)or Co(naphthenate) claim 29 , Co(II)oxalate claim 29 , Co(acac) claim 29 , Co(acac) claim 29 , Co(salen) claim 29 , Co(salen)Cl claim 29 , Mn(salen) and Mn(salen)Cl claim 29 , and Mn(acac) claim 29 , where acac is acetylacetonate and salen is the N claim 29 ,N′-bis(salicylidene)ethylenediamino ligand.31. The process according to claim 24 , wherein the at least one transition metal is employed in a total amount of from 5×10to 0.5 mol per mole of the compound of the formula II.32. The process according to claim 24 , wherein the reaction with the oxidant is carried out in the presence of a complex ligand which has at least one nitrogen atom suitable for coordination with the transition metal.33. The process according to claim 34 , wherein the ligand has at least one group suitable for ...

METHOD FOR PRODUCING OPTICALLY ACTIVE 1,2-BIS(DIALKYLPHOSPHINO)BENZENE DERIVATIVE

An industrially advantageous method for producing an optically active 1,2-bis(dialkylphosphino)benzene derivative of the present invention is provided. The method is characterized in that a phosphine-borane compound represented by the following general formula (1) is subjected to a deboronation reaction, followed by lithiation, then the reaction product is subjected to reaction with an alkyldihalogenophosphine represented by RPX′, and thereafter the reaction product is subjected to reaction with a Grignard reagent represented by RMgX″ to produce an optically active 1,2-bis(dialkylphosphino)benzene derivative (A). Rand Rrespectively represent an alkyl group having 1 to 8 carbon atoms, and the number of carbon atoms is different between Rand R. Ris either Ror Rand Ris the other of Rand R. X, X′, and X″ each represent a halogen atom. 2. A method for asymmetric hydrogenation using a transition metal complex having optically active 1 claim 1 ,2-bis(dialkylphosphino)benzene derivative produced by the method of as ligand claim 1 , as a catalyst. The present invention relates to a method for producing an optically active 1,2-bis(dialkylphosphino)benzene derivative.An optically active phosphine ligand having a chiral center on a phosphorous atom plays an important role in a catalytically asymmetric synthesis reaction using a transition metal complex. A 1,2-bis(dialkylphosphino)benzene derivative has been suggested as an optically active phosphine ligand having a chiral center on a phosphorous atom, for example, in PTL 1. A transition metal complex having this benzene derivative as a ligand is a compound having excellent property as a catalyst for asymmetric synthesis. A method for producing the above mentioned benzene derivative by using 1,2-bis(phosphino)benzene as a stating material is described in PTL 1.Also, a method for producing an optically active 1,2-bis(dialkylphosphino)benzene derivative is described in NPL 1. In above method, chromium 1,2- ...

Ionic Viscoelastics and Viscoelastic Salts

One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials.

DIPHOSPHONATE COMPOUND AND A METHOD FOR PREPARING THE SAME AND AN APPLICATION OF THE SAME

The present disclosure relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higher activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration schedule for the diphosphonate compound is provided. 3. The compound according to claim 2 , characterized in that Ris H or OH.4. The compound according to claim 2 , characterized in that Ris halogen.5. The compound according to claim 4 , characterized in that Ris F claim 4 , Cl or Br.9. The compound according to claim 2 , characterized in that Ris Se.10. The compound according to claim 2 , characterized in that R claim 2 , R claim 2 , Rand Rare hydrogen.12. A method for preparing the compound according to claim 1 , comprising the following steps:(1). Proton activation of methylene:Tetraisopropylmethylenediphosphonate and NaH are performed with the proton activation reaction of methylene for 1 h-4 h under −5° C.-40° C., with the mole ratio of NaH and tetraisopropylmethylendiphosphonate being 1:1-3:1;(2). alkylation reaction:The compound A substituted by bromine and nitro is added to the reaction liquid resulted from step (1) to perform alkylation reaction under 60° C.˜150° C. for 2 h˜5 h, the mole ratio of compound A and tetraisopropylmethylenediphosphonate is 1:1-3:1; after reaction organic solvent is added to the reaction liquid for extraction, the organic phase is collected and evaporated to dryness, and compound I with the methylene substituted by the compound comprising nitro group is obtained;(3). reduction of nitro:10% Pd/C catalyst is added to the alcohol solution of compound I obtained in step (2) and hydrogen gas is inlet, reacted under room temperature with 0.1 MPa-2 MPa of Hydrogen pressure in ...

Zwitterionic lipids

In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent to a subject in treating or diagnosing disease in that subject.

INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD

The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes. 142-. (canceled)44. The process according to claim 43 , wherein step (a) is conducted in the presence of a Friedel-Crafts catalyst claim 43 , a metal salt of an organic acid claim 43 , or a protic acid claim 43 , wherein{'sub': 3', '3', '4', '4', '2', '3, 'the Friedel Crafts catalyst is selected from AlCl, FeCl, SnCl, TiCl, ZnCland BF;'}the metal salt of an organic acid is a metal triflate selected from hafnium triflate and cerium triflate; and{'sub': 2', '4', '3', '3, 'the protic acid is selected from HF, HSO, CFSOH and an ion-exchange resin which is selected from Nafion or zeolite.'}45. The process according to claim 43 , wherein the reducing agent in step (b) is NaBH.46. The process according to claim 43 , wherein the hydroxy protecting group P in compound (13A) is acetyl (COCH) claim 43 , and wherein in step (c) the protection of 3-nitro-1-(4-octylphenyl)propan-1-ol is carried out by acylation with acetic anhydride or acetyl chloride in the presence of a base.47. The process according to claim 43 , whereinthe reduction of 3-nitro-1-(4-octylphenyl)propan-1-one (12) to 3-nitro-1-(4-octylphenyl)propan-1-ol and its conversion to compound (13A) is carried out in one step without isolation of intermediates; orwherein in step (d) the bis-hydroxymethylation of compound (13A) is carried out with formaldehyde or paraformaldehyde in the presence of a base; orwherein in step (d) the bis-hydroxymethylation of compound (13A) and deprotection to compound (14) is carried out in one step without isolation of intermediates.48. The process according to claim 43 , wherein the reduction step (e) comprises hydrogenating compound (14) to Fingolimod (1) in the presence of a Pd/C catalyst.50. The process according to claim 49 , wherein step (a) is ...

METHOD FOR PRODUCING CYCLIC SILANE COMPOUND OR SALT THEREOF, SALT HAVING CYCLIC SILANE DIANION, AND CYCLIC SILANE DIANION SALT-CONTAINING COMPOSITION

An object of the present invention is to provide a production method that can efficiently produce a cyclic silane compound or a salt thereof with a high yield and to provide a novel salt having a cyclic silane dianion that is easy to handle and a cyclic silane dianion salt-containing composition. The method for producing a cyclic silane compound or a salt thereof of the present invention includes the step of allowing a halosilane compound to react in the presence of at least one of a phosphonium salt and an ammonium salt, and a compound represented by a specific formula. 2. The method for producing a cyclic silane compound or a salt thereof according to claim 1 , wherein the reaction is carried out in the presence of a basic compound.3. The method for producing a cyclic silane compound or a salt thereof according to claim 1 , wherein the phosphonium salt or the ammonium salt is a quaternary phosphonium salt or a quaternary ammonium salt.7. The cyclic silane dianion salt-containing composition according to claim 6 , wherein the salt having a cyclic silane dianion represented by the general formula (vii) is contained in an amount of 1 to 10000 parts by mass claim 6 , based on the total amount of 100 parts by mass of the salt having a cyclic silane dianion represented by the general formula (vi).8. The method for producing a cyclic silane compound or a salt thereof according to claim 2 , wherein the phosphonium salt or the ammonium salt is a quaternary phosphonium salt or a quaternary ammonium salt. (1) Field of the InventionThe present invention relates to a production method that can efficiently obtain a cyclic silane compound or a salt thereof by a simple method, a novel salt having a cyclic silane dianion, and a cyclic silane dianion salt-containing composition.(2) Description of Related ArtA silane compound is widely utilized as a raw material of silicon and silica, and a water-reactive combustible gas such as monosilane and disilane is mostly used. On the other ...

ISOMERIZATION OF OLEFINIC COMPOUNDS

The present invention relates to a process for preparing an olefinically unsaturated phosphonium salt having at least two olefinic double bonds, of which one double bond has a Z or cis conformation and the second or a further double bond an E conformation, from an olefinically unsaturated phosphonium salt having at least two olefinic double bonds of different configuration compared to the target compound, and both especially have an all-E or all-trans conformation. In addition, the invention provides for the use of the compound obtained by the process for provision of terpenoid substances as medicaments. 115.-. (canceled)17. The process according to claim 16 , wherein Xis selected from the group consisting of halide claim 16 , dihydrogenphosphate claim 16 , nitrate claim 16 , hydrogensulfate claim 16 , sulfate claim 16 , chlorate claim 16 , perchlorate claim 16 , tetrafluoroborate claim 16 , C1-C4-alkanoates claim 16 , and C1-C7-sulfonates.18. The process according to claim 16 , wherein the isomerization is a thermal isomerization.19. The process according to claim 18 , wherein the thermal isomerization is performed within a temperature range from 50 to 200° C.20. The process according to claim 18 , wherein the thermal isomerization is performed within a temperature range from 100° C. to 180° C.21. The process according to claim 18 , wherein the thermal isomerization is performed within a temperature range from 120° C. to 180° C.22. The process according to claim 16 , wherein the isomerization is performed within a pressure range from 1 to 100 bar.23. The process according to claim 22 , wherein the isomerization is performed within a pressure range from 5 to 80 bar.24. The process according to claim 22 , wherein the isomerization is performed within a pressure range from 8 to 50 bar.25. The process according to claim 22 , wherein the isomerization is performed within a pressure range from 10 to 25 bar.26. The process according to claim 16 , wherein the isomerization ...

Ionic Viscoelastics and Viscoelastic Salts

One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials. 2. The salt of claim 1 , wherein Y is —[CO].3. The salt of claim 1 , wherein X and W are the same.5. The salt of claim 1 , wherein R is a bond to W or is selected claim 1 , independently for each occurrence claim 1 , from the group consisting of hydrogen or alkyl.6. The salt of claim 1 , wherein said cationic component is W—[Z].7. The salt of claim 6 , wherein said anionic component is X—[Y]; X is C(R′)(A-) claim 6 , C(R′)[(AO)A-] claim 6 , C(R′)[(ANH)A-] claim 6 , N(A) claim 6 , N[(AO)A-] claim 6 , or N[(ANH)A-]; A is claim 6 , independently for each occurrence claim 6 , —(CQ)-; Q is claim 6 , independently for each occurrence claim 6 , hydrogen or methyl; p is claim 6 , independently for each occurrence claim 6 , 0-40 inclusive; and R′ is hydrogen claim 6 , halogen claim 6 , azide claim 6 , alkyl claim 6 , aralkyl claim 6 , alkenyl claim 6 , alkynyl claim 6 , cycloalkyl claim 6 , hydroxyl claim 6 , alkoxy claim 6 , aryloxy claim 6 , aryl claim 6 , heteroaryl claim 6 , heteroaralkyl ...

METHOD FOR PRODUCING TRIARYLORGANOBORATES

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms. 1. Process for preparing triaryl organoborates of the formula 1/n KRB—R(IV) , where one equivalent of organoboronic ester of the formula B—R(OR)(OR) (I) is initially charged together with 1/n equivalents of salt K nX (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1 , 3 equivalents of a haloaromatic R—Y (III) are added , an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n K RB—R(IV) is separated off with the organic phase and{'sup': '1', 'sub': 1', '22', '3', '22', '3', '22', '5', '7', '7', '13, 'Ris an optionally hydroxyl- and/or alkoxy- and/or acyloxy- and/or halogen-substituted C- to C-alkyl, C- to C-alkenyl, C- to C-alkynyl, C- to C-cycloalkyl or C- to C-aralkyl radical,'}{'sup': 2', '3', '2', '3, 'sub': 1', '22', '3', '7, 'Rand Rare independently an optionally branched C- to C-alkyl radical or an optionally alkyl-substituted C- to C-cycloalkyl radical or Rand Rtogether form a 2-8-membered carbon bridge which is optionally substituted by alkyl and/or interrupted by oxygen atoms,'}{'sup': '4', 'sub': 6', '10', '1', '4', '1', '4, 'Ris a C- to C-aryl radical optionally substituted by at least one radical selected from halogen, C- to C-alkyl, trifluoromethyl, C- to C-alkoxy, trifluoromethoxy, phenyl and phenoxy,'}K is an organocation of valency n and having any substitution, based on nitrogen, phosphorus, oxygen, sulfur and/or iodine, and{'sup': 2', '3, 'L is an auxiliary that forms a complex of sparing solubility in S1 and/or S2 with M salts MY(OR), MY(OR) and MXY, where L is a Lewis-basic compound, especially selected from the group consisting of open chain ...

NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME

Disclosed are salts of nucleoside analogs and methods of forming the salts. An anion of a nucleoside analog is paired with a permanent counter cation to form a salt that has decreased melting point and increased aqueous solubility compared to the nucleoside compound prior to the salt formation. Also a cation of a nucleoside analog is paired with a permanent counter anion to form a salt that has decreased melting point and increased aqueous solubility compared to the nucleoside compound prior to the salt formation. The nucleoside analog in some embodiments has therapeutic activity such as antiviral. The permanent counter cation or anion in some embodiments has bioactivity such as antibacterial or being a vitamin. 1. A salt , comprising: at least one kind of anion that is anion of a nucleoside analog and at least one kind of cation that is a permanent counter cation , or at least one kind of cation that is a cation of a nucleoside analog and at least one kind of anion that is a permanent counter anion , wherein the aqueous solubility of the salt is greater than the aqueous solubility of the nucleoside analog.2. The salt of claim 1 , wherein the nucleoside analog comprises an ionizable purine or pyrimidine base.3. The salt of claim 1 , wherein the nucleoside analog comprises a guanosine analog antiviral drug.4. The salt of claim 3 , wherein the guanosine analog antiviral drug comprises acyclovir or a pharmaceutically effective salt thereof.5. The salt of claim 1 , wherein the cation is an aprotic cation including quaternary nitrogen or a phosphorous or sulfur-containing analog thereof.6. The salt of claim 1 , wherein the cation is an ammonium cation of the structure NRRRR claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare each independently selected from substituted or unsubstituted Calkyl claim 1 , substituted or unsubstituted Calkenyl claim 1 , substituted or unsubstituted Calkynyl claim 1 , substituted or unsubstituted aryl claim 1 , substituted or ...

Modified Creatine Compounds

The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each Ris independently hydrogen, alkyl, or a phosphate group; Ra linker; Ris a spacer group; Ris hydrogen, alkyl, aryl, or heterocyclic; or Rand R, or Rand R, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl. 2. A compound of wherein{'sub': 5', '5', '5', '5', '5', '5', '1-6, 'Z is —C(═O)NR—, —OC(═O)NR—, —NRC(═O)O—, or —NRC(═O)NR—; wherein each Ris independently hydrogen, or Calkyl;'}Y is a cationic phosphonium group;{'sub': '1', 'each Ris independently hydrogen, alkyl, or a phosphate group;'}{'sub': '2', 'Ris alkyl, cycloalkyl, heterocycloalkyl, or alkylaryl;'}{'sub': '3', 'Ris alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, or alkylaryl;'}{'sub': 4', '1-6, 'Ris hydrogen, or Calkyl; and W is hydrogen.'}3. A compound of wherein Z is —C(═O)NR— claim 2 , and Ris hydrogen claim 2 , or Calkyl.4. A compound of wherein Z is —C(═O)NH—.5. A compound of wherein a cationic phosphonium group is selected from —P(R′)X claim 2 , wherein R′ is alkyl or aryl; and X is an anion.6. A compound of wherein R′ is phenyl; and X is chloride claim 5 , or trifluoroacetate.7. A compound of wherein each Ris hydrogen.8. A compound of wherein one Ris hydrogen claim 2 , the other Ris —POM claim 2 , wherein M is a cation having one or two position charges.9. A compound of wherein Ris straight or branched Calkyl.10. A compound of wherein Ris Calkyl.11. A compound of wherein Ris alkyl claim 2 , cycloalkyl claim 2 , alkylcycloalkyl claim 2 , heterocycloalkyl claim 2 , or alkylheterocycloalkyl claim 2 , wherein alkyl is straight or branched.12. A compound of wherein Ris Calkyl.13. A compound of wherein Ris Calkylcycloalkyl ...

METHODS FOR PREPARATION OF LYCOPENES FROM C15-WITTIG SALTS AND METHODS FOR PURIFICATION OF HIGH ALL-E CONTAINING AND HIGH 6Z CONTAINING C15-WITTIG SALTS

The present invention relates to methods for preparation of lycopenes, especially to lycopenes with high all-E contents or high 6Z contents from C15-Wittig slats mixtures. (with high all-E-contents and high 6Z-contents, respectively). C15-Wittig slats mixtures are purified and 6Z-C15-Wittig salts are extracted from the mixtures. The extracted 6Z-C15-Wittig salts are, used in the synthesis of lycopenes with high 6Z contents and the residues are used in the synthesis of lycopenes with high All-E contents. 1. A method for purification of C15-Wittig salts to obtain high all-E contents , comprising the steps of:obtaining a C15-Wittig salt cis/trans mixture;purifying the C15-Wittig salt cis/trans mixture to remove solvents;adding an aprotic solvent to the C15 Wittig salt cis/trans mixture to extract 6Z-C15-Wittig salts from the mixture;removing the 6Z-C15-Wittig salts from the mixture to obtain residues; andpurifying the obtained residues to obtain C15-Wittig salts;characterized in that the aprotic solvent comprises acetone.2. The method according to claim 1 , wherein purification of the C15 Wittig salt cis/trans mixture includes adding the aprotic solvent to the C15 Wittig salt cis/trans mixture and stirring the composition at 30° C. for over 10 hours.3. The method according to claim 2 , wherein the aprotic solvent includes ethyl acetate.4. The method according to claim 2 , wherein the composition is stirred for 16 hours.57-. (canceled)8. The method according to claim 1 , wherein purification of the residue includes adding the aprotic solvent to the C15 Wittig salt cis/trans mixture and stirring the composition at 25° C. to −30° C. for over 10 hours.9. The method according to claim 8 , wherein the aprotic solvent includes ethyl acetate.10. (canceled)11. A method for purification of C15-Wittig salts to obtain high 6Z contents claim 8 , comprising the steps of:obtaining a C15-Wittig salt cis/trans mixture;purifying the C15-Wittig salt cis/trans mixture to remove solvents; ...

PHOSPHONIUM COMPOUND, EPOXY RESIN COMPOSITION INCLUDING THE SAME AND SEMICONDUCTOR DEVICE PREPARED USING THE SAME

A phosphonium compound, an epoxy resin composition including the same, a semiconductor device encapsulated with the same, and a method of encapsulating a semiconductor device, the phosphonium compound being represented by Formula 1: 2. The phosphonium compound as claimed in claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare each independently a Cto Caryl group.3. The phosphonium compound as claimed in claim 2 , wherein at least one of R claim 2 , R claim 2 , R claim 2 , and Ris substituted with a hydroxyl group.4. The phosphonium compound as claimed in claim 1 , wherein M is sodium or potassium.6. An epoxy resin composition claim 1 , comprising:an epoxy resin;a curing agent;an inorganic filler; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a curing catalyst, wherein the curing catalyst includes the phosphonium compound as claimed in .'}7. The epoxy resin composition as claimed in claim 6 , wherein the epoxy resin includes a bisphenol A epoxy resin claim 6 , a bisphenol F epoxy resin claim 6 , a phenol novolac epoxy resin claim 6 , a tert-butyl catechol epoxy resin claim 6 , a naphthalene epoxy resin claim 6 , a glycidylamine epoxy resin claim 6 , a cresol novolac epoxy resin claim 6 , a biphenyl epoxy resin claim 6 , a linear aliphatic epoxy resin claim 6 , a cycloaliphatic epoxy resin claim 6 , a heterocyclic epoxy resin claim 6 , a spiro ring-containing epoxy resin claim 6 , a cyclohexane dimethanol epoxy resin claim 6 , a trimethylol epoxy resin claim 6 , or a halogenated epoxy resin.8. The epoxy resin composition as claimed in claim 6 , wherein the curing agent includes a phenol resin.9. The epoxy resin composition as claimed in claim 6 , wherein the curing agent includes a phenol aralkyl phenol resin claim 6 , a phenol novolac phenol resin claim 6 , a xyloc phenol resin claim 6 , a cresol novolac phenol resin claim 6 , a naphthol phenol resin claim 6 , a terpene phenol resin claim 6 , a polyfunctional phenol resin claim 6 , a ...

ONO Pincer Ligands and ONO Pincer Ligand Comprising Metal Complexes

Embodiments of the invention are directed to ONO pincer ligands that can be in a trianionic, protonated or protonated equivalent form. The ONO pincer ligand can be combined with a metal comprising compound to form an ONO pincer ligand comprising transition metal complex. By choice of the ONO pincer ligand structure, the steric and electronic properties of the metal complexes therefrom can be controlled. The ONO pincer ligands comprise a central nitrogen atom that is disubstituted with a pair of three atom comprising bridges where the three atoms are a pair of sphybridized carbons and an sphybridized carbon. 3. A method of preparing an ONO pincer ligand precursor according to claim 1 , comprising condensing a nucleophilic oxygen or nucleophilic nitrogen comprising compound with an electrophilic carbon comprising compound further comprising the bridge structure of the resulting ONO pincer ligand.4. A trianionic ONO pincer ligand comprising metal complex comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'at least one ONO trianionic pincer ligand derived from the ONO trianionic pincer ligand precursor of ; and'}a metal.5. The trianionic ONO pincer ligand comprising metal complex of claim 4 , wherein the metal is a transition metal from group III through group X of the periodic table.13. The method of preparing an ONO pincer ligand comprising metal complex of claim 11 , wherein the precursor metal compound further comprises a metal alkylidyne claim 11 , further comprising adding the OH or NH of the ONO pincer ligand precursor across the metal alkylidyne to form the anionic ONO pincer ligand comprising metal complex. This application is a divisional of U.S. application Ser. No. 14/077,822, filed Nov. 12, 2013, which is a continuation-in-part of International Patent Application No. PCT/US2012/037302, filed May 10, 2012, which claims the benefit of U.S. Provisional Application Ser. No. 61/484,793, filed May 11, 2011, the disclosures of which are hereby ...

PHOSPHONIUM COMPOUND AND PRODUCTION METHOD THEREFOR

The present invention provides a phosphonium compound of formula (II). Also provided is a method for producing a quaternary phosphonium compound labeled with a positron emitting radionuclide, the method comprising the step of reacting an electrophile of formula (I): X-CH-Awith triphenylphosphine having one or more radionuclide-labeled substituents on the benzene ring to give a quaternary phosphonium salt. 2. The phosphonium compound according to claim 1 , wherein the radionuclide is a positron emitting nuclide.3. The phosphonium compound according to claim 2 , wherein the positron emitting nuclide is F.4. The phosphonium compound according to claim 1 , wherein Ais a hydrogen atom claim 1 , Calkyl optionally substituted with one or more halogen atoms claim 1 , phenyl claim 1 , or phenylCalkyl claim 1 , wherein the phenyl or a phenyl moiety of phenylCalkyl is optionally substituted with one or more substituents selected from one or more halogen atoms claim 1 , Calkyl claim 1 , Calkoxy claim 1 , Calkylthio claim 1 , cyano claim 1 , amino claim 1 , Calkylamino claim 1 , di(Calkyeamino claim 1 , nitro claim 1 , hydroxy claim 1 , and (Calkoxy)carbonyl.5. The phosphonium compound according to claim 1 , wherein the phosphonium compound comprises a phosphonium selected from:{'sup': '18', 'benzyl-[4-(2-[F]fluoroethoxy)phenyl]-diphenylphosphonium;'}{'sup': '18', 'benzyl-(4- [2- {2-(2-[F]fluoroethoxy)ethoxy}ethoxy]phenyl)-diphenylphosphonium;'}{'sup': '18', '[4-(2-[F]fluoroethoxy)phenyl]-(4-methoxycarbonylphenyl)methyl-diphenylphosphonium;'}{'sup': '18', '[4-(2-[F]fluoroethoxy)phenyl]-(4-fluorophenyemethyl-diphenylphosphonium;'}{'sup': '18', '[4-(2-[F]fluoroethoxy)phenyl]-(3,4,5-trifluorophenyl)methyl-diphenylphosphonium;'}{'sup': '18', '(4-chlorophenypmethyl-[4-(2-[F]fluoroethoxy)phenyl]-diphenylphosphonium;'}{'sup': '18', '[4-(2-[F]fluoroethoxy)phenyl]-(4-methoxyphenyl)methyl-diphenylphosphonium;'}{'sup': '18', '[4-(2-[F]fluoroethoxy)phenyl]-(n-pentyl)-diphenylphosphonium ...

IONIC LIQUIDS COMPRISING HETERAROMATIC ANIONS

Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein. 2. The ionic liquid of claim 1 , wherein Rand Rare H and Ris NO.4. The method of claim 3 , wherein the mixture of gases is an exhaust from combustion of a carbon-based fuel claim 3 , wherein the carbon-based fuel is coal claim 3 , a petroleum product claim 3 , or natural gas.5. The method of claim 3 , wherein the mixture of gases further comprises an oxide of sulfur or nitrogen.6. The method of claim 3 , further comprising recovering the carbon dioxide from the second ionic liquid by applying at least one of heat or reduced pressure to the second ionic liquid.8. The gas separation system of claim 3 , further comprising a regeneration component wherein the ionic liquid according to is subjected to heat and/or reduced pressure to liberate carbon dioxide.9. A combustion device comprising:a combustion vessel configured to contain a combustion reaction;an exhaust component, in fluid communication with the combustion vessel, which is configured to allow exhaust from the combustion reaction to escape from the combustion vessel, wherein the exhaust comprises carbon dioxide; and{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'the gas separation system of , coupled to the exhaust component;'}wherein the device is configured to provide sufficient contact between the exhaust and the separation system to remove at least a portion of the carbon dioxide from the exhaust. This application is a continuation of U.S. patent application Ser. No. 15/802,360, filed on Nov. 2, 2017, which is a divisional of U.S. patent application Ser. No. 13/505,730, filed on May 2, 2012, now U.S. Pat. ...

USE OF SILVER(I) COMPLEXES AS ANTICANCER AGENTS

The present invention relates to the use of silver(l) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer. 122-. (canceled)24. The use according to claim 23 , wherein the R groups are the same or different.25. The use according to claim 23 , wherein the R groups are independently selected from the group of substituents consisting of hydrogen claim 23 , Cto Ostraight or branched or cyclic alkyl moieties claim 23 , Caryl moieties claim 23 , metallocene moieties and adamantyl moieties claim 23 , wherein the said moieties may be unsubstituted or substituted by one or more substituents selected from the group consisting of Cto Ostraight or branched or cyclic alkyl moieties claim 23 , alkoxy moieties claim 23 , haloalkyl moieties claim 23 , hydroxyl moieties claim 23 , carbonyl moieties claim 23 , aldehyde moieties claim 23 , haloformyl moieties claim 23 , carboxylic moieties claim 23 , ester moieties claim 23 , amine moieties claim 23 , imine moieties and sulfide moieties.26. A pharmaceutical composition comprising a silver(I) monophosphine complex according to Formula (I) or pharmaceutically acceptable salts claim 23 , polymorphs or derivatives thereof claim 23 , as defined according to claim 23 , in combination with one or more pharmaceutically acceptable excipients claim 23 , additives or carriers.27. The use of a silver(I) monophosphine complex according to Formula (I) or pharmaceutically acceptable salts claim 23 , polymorphs or derivatives thereof claim 23 , as defined according to claim 23 , in the manufacture of a medicament for the treatment claim 23 , diagnosis and/or prevention of cancer.28. The use of a silver(I) monophosphine complex according to Formula (I) or ...

1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof. 3. The method as claimed in claim 1 , wherein the irradiation of the microorganisms and of the at least one photosensitizer with electromagnetic radiation of a suitable wavelength and energy density is carried out in the presence of at least one oxygen-donating compound and/or at least one oxygen-containing gas.6. The method according to claim 5 , wherein said microorganisms are selected from the group consisting of viruses claim 5 , archaea claim 5 , bacteria claim 5 , bacterial spores claim 5 , fungi claim 5 , fungal spores claim 5 , protozoa claim 5 , algae and blood-transmissible parasites.7. The method according to claim 5 , wherein the microorganisms on or within the patient are brought into contact with the at least one photosensitizer in at least one selected from the group consisting of cleaning of teeth claim 5 , dental prostheses and dental braces claim 5 , treatment of a disease of the dental tissue and of the periodontium.8. The method according to claim 5 , wherein the microorganisms on or within the patient are brought into contact with the at least one photosensitizer for treatment of an infectious skin disease.9. The method according to claim 5 , wherein the microorganisms on or within the patient are brought into contact with the at least one photosensitizer for reduction of the bacterial count in a wound. The present application is a divisional of prior U.S. patent application Ser. No. 15/755,166, filed Feb. 26, 2018, by Andreas SPÄTH, Kristjan PLÄTZER, Tim MAISCH and Anja EICHNER, entitled “1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF,” which is a 35 U.S.C. §§ 371 national phase conversion of PCT/EP2016/070234, filed Aug. 26, 2016, which claims priority to European Patent Application No. 15182597.3, filed Aug. 26, 2015. The PCT International Application was published in the German language. The contents of ...

UV-CURABLE PHOSPHONIUM SMALL MOLECULES AS ANTIMICROBIAL COATINGS AND SURFACE ACTIVE ADDITIVES

The attachment and proliferation of antibiotic resistant, biofilm-forming bacteria to oft-handled material surfaces has emerged as a growing concern, particularly in the biomedical, healthcare and food packaging industries. UV-curable phosphoniums bearing benzophenone anchors have been synthesized with a variety of alkyl, aryl, and fluoroalkyl functional groups at phosphorus to probe their efficacy as thermally stable antimicrobial additives in plastics or as surface coatings. In an embodiment, a phosphonium compound having the following formula has been synthesized: 2. The phosphonium compound according to claim 1 , wherein the alkyl has a general formula CHwherein n is an integer ranging between 1 and 18.3. The phosphonium compound according to claim 1 , wherein the substituted alkyl has a general formula CXwherein X is hydrogen and/or one or more of substituents claim 1 , and n is an integer ranging between 1 and 18.4. The phosphonium compound according to claim 1 , wherein the substituted alkyl has a number of carbon atoms in a range between 1 and 18.5. The phosphonium compound according to claim 3 , wherein the substituents comprise fluorine.6. The phosphonium compound according to claim 1 , wherein the substituted aryl has substituents at any one claim 1 , or more of claim 1 , ortho claim 1 , meta and para positions.7. The phosphonium compound according to claim 6 , wherein the substituents comprise an alkyl or a heteroalkly claim 6 , wherein the alkyl backbone is optionally substituted.8. The phosphonium compound according to claim 7 , wherein the alkyl backbone is substituted with fluorine.11. The phosphonium compound according to claim 10 , combined as an additive with a polymer for forming an antimicrobial composite material.12. The antimicrobial composite material according to claim 11 , wherein said polymer is a thermoplastic polymer claim 11 , and wherein said phosphonium compound (2) is covalently bound to the thermoplastic polymer lattice.13. The ...

NOVEL PYRAZINE AMIDE COMPOUNDS

The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, 2. The compound according to wherein Ris selected from methyl claim 1 , HO(O)C—CH— claim 1 , CHO(O)C—CH— claim 1 , Cl(CH)N—CH—CH—HN(O)C—CH— and phenyl.3. The compound according to wherein Rand Rare together Rand Ris selected from C-alkylene each optionally partially or fully substituted with R claim 1 ,wherein Ris selected from phenyl claim 1 , optionally substituted with C-alkyl.4. The compound according to wherein Rand Rare together R claim 3 , wherein Ris selected from —CH—CH— claim 3 , —CH—CH—CH— claim 3 , —CH—CH—CH—CH— each optionally partially or fully substituted with R claim 3 , wherein Ris selected from phenyl claim 3 , optionally substituted with CH—.6. The compound according to wherein Rand Rare together —CH—.7. The compound according to wherein Ris selected from H or CH.8. The compound according to wherein Ris H.9. The compound according to wherein Ris selected from C-alkyl.10. The compound according to wherein Ris CH.11. The compound according to wherein Ris selected from{'sub': 1-4', '5-6', '1-4', '2', '5-6', '2', '1-4, 'C-alkyl optionally substituted with one or two groups selected from C-cycloalkyl, indolyl, HO(O)C—, C-alkyl-O(O)C—CH—, C-cycloalkyl-O(O)C—CH—, phenyl-O— optionally substituted with C-alkyl-O—,'}{'sup': 3.1', '3.1', '3.1', '3.1, 'sub': 2', '2, 'phenyl substituted with two halogen, phenyl optionally substituted with one R—, R—O—, R—CH—, R—CH—O—, halogen or NC—,'}{'sup': 3.1', '3.1.1', '3.1.1', '3.1.2', '3.1.2, 'sub': 1-4', '1-4', '2', '1-4', '2', '1-4', '2', '2', '2', '2', 'n', '2', '2, 'wherein Ris independently selected from H, C-alkyl, benzyl, HO(O)C—, C-alkyl-O(O)C—, HO—CH—, C-alkyl-O—CH—, (C-alkyl)N—CH—, H—[O—CH—CH]—, RHN(O)C—, (R)N(O)C—, RHN(O)C— or (R)N(O)C—,'}n is 3, 4 or 5,{'sup': '3.1.1', 'sub': 2', '2', '2', '2', '2', '3', '1-4', '1-4', '1-4, 'Ris independently selected from H, H—[O—CH—CH]— or H—[O—CH—CH]— or a five or six- ...

PHOSPHONIUM SALTS AND METHODS OF THEIR PREPARATION

Methods for preparing phosphonium salts by reacting a primary phosphine or a secondary phosphine with an ester compound selected from the group consisting of: a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester; to form a phosphonium salt of formula VII 2. The method of claim 1 , wherein Ris hydrogen and Ris a hydrocarbyl.3. The method of claim 1 , wherein each of Rand Rare both hydrocarbyl.4. The method of claim 1 , wherein the hydrocarbyl is a substituted or unsubstituted alkyl group of 1 to 20 carbon atoms.5. The method of claim 4 , wherein the hydrocarbyl is selected from the group consisting of: methyl claim 4 , trifluoromethyl claim 4 , ethyl claim 4 , n-propyl claim 4 , iso-propyl claim 4 , n-butyl claim 4 , iso-butyl claim 4 , tert-butyl claim 4 , cyclopentyl claim 4 , cyclohexyl claim 4 , and norbornyl.6. The method of claim 3 , wherein Rand Rtogether with the phosphorus atom to which Rand Rare bonded form a five- to eight-membered heterocycle or heterobicycle.7. The method of claim 6 , wherein the heterobicycle is 9-phosphabicyclo[3.3.1]nonyl.8. The method of claim 1 , wherein Ris selected from the group consisting of: methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , iso-propyl claim 1 , n-butyl claim 1 , iso-butyl claim 1 , and tert-butyl.9. The method of claim 8 , wherein Ris methyl.10. The method of claim 1 , wherein the sulfonate ester is methyl tosylate.11. The method of claim 1 , wherein the phosphonium salt has a total number of carbon atoms between 20 and 50.12. The method of claim 11 , wherein the phosphonium salt has a total number of carbon atoms between 25 and 50.13. The method of claim 1 , wherein the phosphonium salt is water immiscible. This application is a divisional application of U.S. patent application Ser. No. 12/899,097, filed Oct. 6, 2010 (pending), which is a divisional of U.S. patent application Ser. No. 10/549,223, filed Feb. 8, 2007 (now U.S. Pat. No. 7,829,744), which is the U.S. National ...

PHOSPHONIUM SALTS AND METHODS OF THEIR PREPARATION

Methods for preparing phosphonium salts by reacting a primary phosphine or a secondary phosphine with an ester compound selected from the group consisting of: a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester; to form a phosphonium salt of formula VII 2. The method of claim 1 , wherein Ris hydrogen and Ris a hydrocarbyl.3. The method of claim 1 , wherein each of Rand Rare both hydrocarbyl.4. The method of claim 1 , wherein the hydrocarbyl is a substituted or unsubstituted alkyl group of 1 to 20 carbon atoms.5. The method of claim 4 , wherein the hydrocarbyl is selected from the group consisting of: methyl claim 4 , trifluoromethyl claim 4 , ethyl claim 4 , n-propyl claim 4 , iso-propyl claim 4 , n-butyl claim 4 , iso-butyl claim 4 , tert-butyl claim 4 , cyclopentyl claim 4 , cyclohexyl claim 4 , and norbornyl.6. The method of claim 3 , wherein Rand Rtogether with the phosphorus atom to which Rand Rare bonded form a five- to eight-membered heterocycle or heterobicycle.7. The method of claim 6 , wherein the heterobicycle is 9-phosphabicyclo[3.3.1]nonyl.8. The method of claim 1 , wherein Ris selected from the group consisting of: methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , iso-propyl claim 1 , n-butyl claim 1 , iso-butyl claim 1 , and tert-butyl.9. The method of claim 8 , wherein Ris methyl.10. The method of claim 9 , wherein the sulfate ester is dimethyl sulfate.11. The method of claim 1 , wherein the phosphonium salt has a total number of carbon atoms between 20 and 50.12. The method of claim 11 , wherein the phosphonium salt has a total number of carbon atoms between 25 and 50.13. The method of claim 1 , wherein the phosphonium salt is water immiscible. This application is a divisional application of U.S. patent application Ser. No. b /,, filed Oct. 6, 2010 (pending), which is a divisional of U.S. patent application Ser. No. 10/549,223, filed Feb. 8, 2007 (now U.S. Pat. No. 7,829,744), which is the U.S. National Phase ...

PLATING SOLUTION USING PHOSPHONIUM SALT

A plating solution including a soluble salt containing at least a stannous salt; an acid selected from organic acid and inorganic acid or a salt thereof; and an additive containing phosphonium salt with two or more of aromatic rings is provided. 2. The plating solution according to claim 1 , wherein {'br': None, 'sub': 3', '1', '2', '4, 'R—Y—Z—Y—R\u2003\u2003(2)'}, 'the additive further comprises a nonionic surfactant represented by a general formula (2) below,'}{'sub': 3', '4, 'claim-text': {'br': None, 'sub': n', '2n', 'm, '—(CH—O)—H\u2003\u2003(A)'}, 'and wherein, in the formula (2), Rand Ris the group represented by the formula (A) below,'}{'sub': 1', '2, 'and wherein, Yand Yrepresent a single bond or a group selected from —O—, —COO— and —CONH—; and Z represents a benzene ring or 2,2-diphenylpropane, and'}in the formula (A), n indicates 2 or 3 and m indicates an integer from 1 to 15.3. The plating solution according to claim 1 , wherein the additive further comprises a complexing agent and an antioxidant; or one of a complexing agent and an antioxidant.4. The plating solution according to claim 2 , wherein the additive further comprises a complexing agent and an antioxidant; or one of a complexing agent and an antioxidant. The present invention relates to a plating solution for tin or a tin alloy which is excellent in uniform electrodepositivity and suppresses generation of voids when a bump electrode is formed.Priority is claimed on Japanese Patent Application No. 2015-064067, filed Mar. 26, 2015, and Japanese Patent Application No. 2016-056773, filed Mar. 22, 2016, the contents of which are incorporated herein by reference.Conventionally, a lead-tin alloy solder plating solution made of an aqueous solution, which contains: at least one selected from an acid and a salt thereof; a soluble lead compound; a soluble tin compound; a nonionic surfactant; and a formalin condensate of naphthalenesulfonic acid or a salt thereof, is disclosed (for example, see Patent ...

Onium salt-containing treatment liquid for semiconductor wafers

Provided is a treatment liquid for a semiconductor wafer or the like used in a process for forming a semiconductor. Namely a treatment liquid containing (A) a hypochlorite ion, and (B) an alkylammonium salt expressed by the following Formula (1), or the like is provided. (In the Formula, “a” is an integer from 6 to 20; R 1 , R 2 , and R 3 are independently, for example, an alkyl group with a carbon number from 1 to 20; and X − is, for example, a chloride ion.)

CATALYTIC RADIOFLUORINATION

One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal. 120-. (canceled)22. The method of claim 21 , wherein the acquired positron emission spectrum is of the mammal's lungs claim 21 , heart claim 21 , liver claim 21 , kidneys claim 21 , blood claim 21 , muscle claim 21 , brain claim 21 , mitochondria claim 21 , or a combination thereof.23. The method of claim 21 , wherein the acquired positron emission spectrum is of a tumor in the mammal.24. The method of claim 21 , wherein the mammal is suffering from cancer or a mitochondrial deficient disease.25. The method of claim 21 , wherein method is a method of screening a mammal for mitochondrial dysfunction; and the mitochondrial dysfunction is a cardiovascular disease claim 21 , a neuropsychiatric disease claim 21 , or a neurodegenerative disease.26. The method of claim 25 , wherein the mitochondrial dysfunction is selected from the group consisting of myocardial perfusion claim 25 , bipolar disorder claim 25 , depression claim 25 , schizophrenia Alzheimer's disease claim 25 , Parkinson's disease claim 25 , Friedreich's ataxia claim 25 , amyotrophic lateral sclerosis claim 25 , Huntington's disease claim 25 , premature ageing ...

IONIC LIQUID FOR FORWARD OSMOSIS PROCESS AND FORWARD OSMOSIS PROCESS

A forward osmosis process is provided, which includes separating a feed part and a draw solution part by a semi-permeable film. An ionic liquid is introduced into the draw solution part, and brine is introduced into the feed part. The brine has an osmotic pressure lower than that of the ionic liquid, so that pure water of the brine permeates through the semi-permeable film, enters the draw solution part, and mixes with the ionic liquid to form a draw solution. The draw solution was obtained out of the draw solution part to be left to stand at room temperature, so that the draw solution separated into a water layer and an ionic liquid layer. The ionic liquid includes 14-. (canceled)68-. (canceled)10. (canceled)12. (canceled)13. The forward osmosis process as claimed in claim 5 , further comprising introducing the ionic liquid layer into the draw solution part after the step of separating the draw solution into the water layer and the ionic liquid layer14. The forward osmosis process as claimed in claim 5 , wherein the step of introducing the brine into the feed part is continuously introducing seawater into the feed part.15. The forward osmosis process as claimed in claim 5 , further comprising a step of stirring the pure water and the ionic liquid in the draw solution part for mixing the pure water and the ionic liquid to form the draw solution. This application claims the benefit of U.S. Provisional Application No. 62/381,187 filed on Aug. 30, 2016, and claims priority from Taiwan Application Serial Number 105139655 filed on Dec. 1, 2016, the entirety of which are incorporated by reference herein.The technical field relates to a draw solute (ionic liquid) for a forward osmosis process.The technical principle of forward osmosis (FO) desalination process utilizes an osmosis pressure difference (between two solutions/solutes in two parts separated by a semi-permeable film) as a driving force. Water in a feed part with a lower osmosis pressure will permeate through a ...

Composition, Film, Laminate Structure, Light-Emitting Device, and Display

Provided is a composition having high thermal durability containing a perovskite compound. 2. The composition according to claim 1 , wherein the component (3) is at least one selected from the group consisting of a compound represented by the formula (X1) and a compound represented by the formula (X6).3. A film using the composition according to or .4. A laminated structure comprising the film according to .5. A light emitting device comprising the laminated structure according to .6. A display comprising the laminated structure according to . The present invention relates to a composition, a film, a laminate structure, a light emitting device, and a display.An LED backlight having a blue LED (light emitting diode) and a composition having luminescence has been developed. In recent years, perovskite compounds have attracting attention as a compound having luminescence contained in the composition (Non-Patent Document 1).However, when a composition containing a perovskite compound as described in Non-Patent Document 1 is used as a light emitting material, further improvement in thermal durability is required.The present invention has been made in view of the above-mentioned problem, and has an object of providing a composition having high thermal durability containing a perovskite compound.In order to solve the above problem, the present inventors have intensively studied, and resultantly reached the following present invention.That is, the present invention includes the following [1] to [6].[1] A composition comprising the following components (1), (2), and (3):(1) Component: perovskite compound having A, B, and X: (A indicates a component positioned at each vertex of a hexahedron having B at the center in a perovskite type crystal structure and is a monovalent cation.B indicates a component positioned at the centers of the hexahedron where A is disposed at each vertex and the octahedron where X is disposed at each vertex in the perovskite type crystal structure and ...

PHOSPHONATE DERIVATIVES AND METHODS OF USE THEREOF IN THE TREATMENT OF ALZHEIMER'S DISEASE

Benzothiazole phosphonate analogs and methods of using the same to inhibit the activity of Amyloid Binding Alcohol Dehydrogenase and in the amelioration or treatment of Alzheimer's disease are provided. 4. A pharmaceutical composition comprising the ABAD inhibitor of and a pharmaceutically acceptable carrier.5. A method for inhibiting the activity of Amyloid Binding Alcohol Dehydrogenase (ABAD) comprising contacting ABAD with an inhibitor of thereby inhibiting the activity of ABAD.6. A method for ameliorating or treating Alzheimer's Disease comprising administering to a subject in need thereof the pharmaceutical composition of thereby ameliorating or treating the subject's Alzheimer's Disease. This application is a continuation-in-part application of PCT/US2013/040707, filed May 13, 2013, which claims the benefit of priority from U.S. Patent Application Ser. No. 61/646,548, filed May 14, 2012, the content of which is incorporated herein by reference in its entirety.This invention was made with government support under Grant Nos. R01GM095355, R37AG037319, and PO1AG017490 awarded by National Institute of General Medical Sciences and the National Institute on Aging. The government has certain rights in the invention.Alzheimer's disease (AD) is one of the most common dementia showing slowly progressive cognitive decline. Alzheimer's brain is characterized by accumulation of amyloid beta peptide (Aβ) and the formation of neurofibrillary tangles. Aβ plays a central role in the development of AD pathology and contributes to neuronal, synaptic, and cognitive malfunction. Mitochondrial and synaptic dysfunction is an early pathological feature of Alzheimer's disease brain (Du, et al. (2010) 107:18670; Du, et al. (2011) . doi:10.1089/ars.2011.4277; Chen, et al. (2010) 20 Suppl 2: S569; Caspersen, et al. (2005) 19:2040; Reddy, et al. (2008) 14:45; Lin & Beal (2006) 12:1241). Studies have highlighted the significance of mitochondrial Aβ accumulation and synaptic mitochondrial ...

IONIC TAGS FOR SYNTHESIS OF OLIGORIBONUCLEOTIDES

The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II): 15-. (canceled)6. An ionic tag linker comprising a photolabile moiety , an ionic moiety and a linker.7. The ionic tag linker of claim 6 , wherein the photolabile moiety is a nitrobenzyl derivative.9. The ionic tag linker of claim 6 , wherein the linker is alkyl claim 6 , glycol or functionalized alkyl.10. The ionic tag linker of claim 6 , wherein the ionic moiety is an imidazolium or phosphonium group; or wherein the ionic moiety comprises a halide; or wherein the ionic moiety comprises Br claim 6 , Cl or I.11. The ionic tag linker of claim 6 , wherein the photolabile moiety is cleavable by photolysis.12. The ionic tag linker of claim 6 , wherein the ionic tag linker is orthogonally cleavable.1356-. (canceled) This application is a Continuation of application Ser. No. 14/240,067 filed May 29, 2014, which is a 371 application of International PCT Application No. PCT/CA2012/000784 filed Aug. 23, 2012, which claims priority to U.S. Provisional Application No. 61/602,373 filed Feb. 23, 2012 and International PCT Application No. PCT/CA2011/000950 filed Aug. 23, 2011, all of which are hereby incorporated by reference in their entirety.The invention relates to the chemical synthesis of oligonucleotides, in particular oligoribonucleotides, in particular solution phase synthesis.The demand for synthetic oligonucleotides has grown exponentially as genome sequencing, functional genomics, and PCR-based detection methods consume enormous quantities of DNA oligonucleotides. In addition, the potential success of new DNA- and RNA-based therapeutic platforms (such as antisense and siRNA gene silencing strategies) currently undergoing clinical trials could result in an unprecedented demand for short synthetic DNA and RNA molecules.RNA interference (RNAi) as potential therapeutics represents a fundamentally new way to ...

PHOSPHONIUM-BASED ZWITTERIONIC MONOMERS AND POLYMERS, AND COMPOSITIONS AND METHODS THEREOF

The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents. 2. The compound of claim 1 , wherein Ris H.3. The compound of claim 1 , wherein Ris a methyl group.4. The compound of claim 1 , wherein each Ris a C-Calkyl group.5. The compound of claim 4 , wherein each Ris a C-Calkyl group.6. The compound of claim 4 , wherein each Ris a C-Calkyl group.7. The compound of claim 1 , wherein each Ris an aryl group.8. The compound of claim 7 , wherein each Ris a phenyl group.9. The compound of claim 1 , wherein the Rs are the same.10. The compound of claim 1 , wherein the Rs are not the same.11. The compound of claim 1 , wherein i is 1.12. The compound of claim 11 , wherein j is an integer selected from 0-3.1422-. (canceled)24. The polymer of claim 23 , wherein Ris H.25. The polymer of claim 23 , wherein Ris a methyl group.26. The polymer of claim 23 , wherein each Ris a C-Calkyl group.27. (canceled)28. (canceled)29. The polymer of claim 23 , wherein each Ris an aryl group.3032-. (canceled)33. The polymer of claim 23 , wherein i is 1.34. The polymer of claim 33 , wherein j is an integer selected from 0-3.3556-. (canceled) This application claims the benefit of priority to U.S. Provisional Application No. 62/897,479, filed Sep. 9, 2019, the entire content of each of which is incorporated herein by reference for all purposes.This invention was made with government support under Grant No. NSF-CHE-CCI-1740630 awarded by the National Science Foundation. The Government has certain rights in the invention.The invention generally relates to chemicals and polymers. More particularly, the invention relates to zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic ...

Mito-Honokiol Compounds and Methods of Synthesis and Use Thereof

The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer. 2. The compound of wherein n is an integer from 1-12.3. The compound of claim 1 , wherein n is 10.4. The compound of claim 3 , wherein the n of both L1 and L2 is an integer from 1-12.5. The compound of claim 4 , wherein n is 10.6. The compound of claim 1 , wherein L2 is H.7. The compound of claim 6 , wherein in L1 n is an integer from 1-12.8. The compound of claim 7 , wherein n is 10.11. A method of reducing or inhibiting tumor growth in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising at least one mito-magnolol compound of claim 1 , wherein the tumor is melanoma claim 1 , lung cancer claim 1 , colon cancer or pancreatic cancer.12. The method of claim 11 , wherein the tumor is a lung cancer.13. The method of claim 11 , wherein the tumor is a metastatic tumor.14. The method of claim 11 , wherein the method further comprises treatment of the patient with an antiglycolytic agent and other standard-of-care drug.15. The method of claim 11 , wherein the antiglycolytic agent is selected from the group consisting of 2-deoxyglucose or 3-bromopyruvate.16. The method of claim 11 , wherein the method further comprises treating the patient with surgery claim 11 , radiation therapy (RT) claim 11 , or chemotherapy (CT) prior to or concurrently with administering the pharmaceutical composition.17. A method of inhibiting claim 1 , or reducing metastasis of a cancer comprising administering an effective amount of a pharmaceutical composition comprising at least one mito-magnolol of to inhibit or reduce metastasis of cancer in the patient claim 1 , wherein the cancer is selected from the group consisting of melanoma claim 1 , colon cancer claim 1 , lung cancer and pancreatic cancer.18. The method of claim 17 , wherein the ...

Rosin-Derived Cationic Compounds and Polymers

Methods for forming rosin-derived cationic compounds are provided. The method can include attaching a cationic group to a conjugated diene on a hydrophenathrene-based ring of a resin acid (e.g., levopimaric acid, abietic acid, dehydroabietic acid, or a mixture thereof) to form a rosin-derived cationic compound. Attaching the cationic group to the conjugated diene on the hydrophenathrene-based ring of the resin acid can be achieved via a Diels-Alder reaction of a dienophile with the hydrophenathrene-based ring of the resin acid. Rosin-derived cationic compounds are also provided. The rosin-derived cationic compound can include a cationic group attached to a conjugated diene on a hydrophenathrene-based ring of a resin acid, wherein the rosin-derived cationic compound further comprises a carboxylic acid group. 1. A rosin-derived cationic compound comprising a cationic group attached to a conjugated diene on a hydrophenathrene-based ring of a resin acid , wherein cationic group comprises an antimicrobial.2. The rosin-derived cationic compound as in claim 1 , wherein the resin acid comprises levopimaric acid claim 1 , abietic acid claim 1 , dehydroabietic acid claim 1 , or a mixture thereof.3. The rosin-derived cationic compound as in claim 1 , wherein the resin acid of the rosin-derived cationic compound further comprises a carboxylic acid group.4. The rosin-derived cationic compound as in claim 1 , wherein the resin acid of the rosin-derived cationic compound further comprises a polymerizable group attached to the resin acid via its carboxylic acid group.5. A rosin-derived polymer formed via polymerization of the rosin-derived cationic compound of .6. The rosin-derived polymer as in claim 5 , wherein the rosin derived polymer has a polydispersity index of about 1 to about 1.5.7. A rosin-derived copolymer formed via polymerization of the rosin-derived cationic compound of and a second monomer.8. The rosin-derived copolymer as in claim 7 , wherein the second monomer is a ...

TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL

The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine. 114.-. (canceled)16. The mitochondrially targeted E/Z isomer of an aliphatic triphenylphosphonium derivative of tamoxifen of general formula I or IA according to claim 15 , wherein Z is selected from the group consisting of citrate claim 15 , acetate claim 15 , lactate claim 15 , tartrate claim 15 , oxalate claim 15 , ascorbate claim 15 , mesylate claim 15 , tosylate claim 15 , sulphate claim 15 , halogenide claim 15 , phosphate claim 15 , and mixtures thereof.20. A method of treating neoplastic disease using the mitochondrially targeted E/Z isomer of an aliphatic triphenylphosphonium derivative of tamoxifen of general formula I or IA according to .21. The method according to claim 20 , wherein the neoplastic disease is selected from the group consisting of carcinoma claim 20 , sarcoma claim 20 , lymphoma and leukemia.22. The method according to claim 20 , wherein the neoplastic disease is selected from the group consisting of astrocytoma claim 20 , neuroblastoma claim 20 , glioblastoma claim 20 , mesothelioma claim 20 , breast cancer ...

SUBSTITUTED BICYCLIC COMPOUNDS

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): 116-. (canceled)19. The compound according to or a salt thereof claim 17 , wherein:{'sub': 2a', '2', '3', '3', '2', '5-6', '3', '2', '2', '3', '2', '2', '2', '3', '2', '3', '3', '2', '3', '3', '2', '2', '4', '2', '2', '4', '3', '2', '3', '3', '2', '3', '3', '2', '2', '3', '2', '2', '2', '2', '3', '2', '3', '2', '2', '2', '3', '3', '2', '1-3', '3', '3', '2', '3', '3', '2', '2', '3', '2', '2', '2', '2', '2', '2', '1-2', '3', '2', '2', '2', '2', '2', '2-3', '2', '2', '3-4', '3', '2', '2', '2', '3', '2', '2', '2', '2', '3', '3', '2', '2', '9', '3', '2', '2', '2', '2', '3', '2', '2', '2', '3', '2', '2', '3', '2', '2', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '2', '3', '2', '2', '2', '2', '3', '2', '2', '2', '2', '2', '3', '2', '3', '3', '2', '3', '3', '3', '3', '2', '1-6', '3', '3', '2', '2', '3', '2', '2', '3', '3', '3', '2', '2', '2', '3', '3', '2', '3', '2', '2', '2', '2', '2', '2', '3', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '3', '2', '3', '2', '3', '3', '2', '2', '3', '2', '2', '2', '2', '3', '2', '3', '2', '3', '2', '3', '2', '2', '2-4', '3', '2', '3', '2', '2', '2', '3', '2', '2', '2', '3', '3', '2', '2', '2', '3', '2', '2', '2', '2', '3', '3', '2', '2', '2', '3', '3', '2', '2', '2', '1-2', '3', '2', '2', '2', '3', '2', '2', '3', '3', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '3', '2', '2', '2', '3', '3', '2', '2', '2', '2', '4', '3', '2', '2', '4', '3', '3', '2', '4', '3', '2', '3', '2', '5', '3', '2', '2', '4-7', '3', '2', '2', '2', '2-4', '3', '2', '2', '2', '3', '2', '2', '2', '2-3', '3', '2', '2', '2', '2', '2', '2', '2', '3', '2', '2', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2-3', '3', ' ...

Rosin-Derived Cationic Compounds and Polymers

Methods for forming rosin-derived cationic compounds are provided. The method can include attaching a cationic group to a conjugated diene on a hydrophenathrene-based ring of a resin acid (e.g., levopimaric acid, abietic acid, dehydroabietic acid, or a mixture thereof) to form a rosin-derived cationic compound. Attaching the cationic group to the conjugated diene on the hydrophenathrene-based ring of the resin acid can be achieved via a Diels-Alder reaction of a dienophile with the hydrophenathrene-based ring of the resin acid. Rosin-derived cationic compounds are also provided. The rosin-derived cationic compound can include a cationic group attached to a conjugated diene on a hydrophenathrene-based ring of a resin acid, wherein the rosin-derived cationic compound further comprises a carboxylic acid group.

CYCLOPENTADIENYLIDENE-PHOSPHORANE CONSTRAINED GEOMETRY COMPLEXES OF RARE EARTH METALS

The invention relates to η:η-cyclopentadienylidene-phosphorane constrained geometry complexes of rare earth metals, abbreviated to η:η-CpPC-CGC, method for production and use of same. The η:η-CpPC-CGCs correspond to the general formula (1), wherein SE=Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb or Lu; X=independently of one another, a mono-anionic diorganoamido-, bistrimethylsilylamido-, halogenido-, alkyl-, aryl-, alkoxo-, aryloxo- or alkylaluminate (AlR) substituent; L=neutral ligand (PR, NR, pyridine), solvent molecule (THF, ether, DMF, DMSO, HMPT, tetrahydropyran THP, tetrahydrothiofuran THT); R=alkyl with up to 1-10 C atoms or mono- or polycyclical aryl with 6 to 20 C atoms; R, R=independently of one another H or methyl; R, R=independently of one another, H or methyl or tertiary butyl or together a substituted cycloalkyl group; R, R=methyl, n-butyl, tertiary butyl or phenyl; R, R=independently of one another H, trimethylsilyl, alkyl with 1-10 C atoms or mono- or polycyclical aryl with 6 to 20 C atoms, and m=0, 1, 2 or 3. 115-. (canceled)18. η:η-CpPC-CGC according to claim 16 , whereinSE=Sc, Y, La, Ce, Nd, Sm or Lu.19. η:η-CpPC-CGC according to claim 17 , whereinSE=Sc, Y, La, Ce, Nd, Sm or Lu.20. η:η-CpPC-CGC according to claim 16 , whereinX=hexamethylenedisilazanide, N,N-dimethylbenzylamine ortho-metallized, N,N, α-trimethylbenzylamine ortho-metallized.21. η:η-CpPC-CGC according to claim 17 , whereinX=hexamethylenedisilazanide, N,N-dimethylbenzylamine ortho-metallized, N,N, α-trimethylbenzylamine ortho-metallized.22. η:η-CpPC-CGC according to claim 16 , wherein the neutral ligand is PR claim 16 , NR claim 16 , pyridine claim 16 , wherein R=an alkyl with up to 1-10 carbon atoms or a mono- or polycyclic aryl with 6 to 20 carbon atoms claim 16 , and the dissolvent molecule is THF claim 16 , ether claim 16 , DMF claim 16 , DMSO claim 16 , HMPT claim 16 , tetrahydropyran claim 16 , tetrahydrothiofuran.23. η:η-CpPC-CGC according to claim 17 , ...

COMPOUNDS FOR TREATMENT OF SENESCENCE-RELATED DISORDERS

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammations, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia. 111.-. (canceled)13. The compound of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group consisting of alkylene claim 12 , alkenylene and alkynylene having 4 to 14 carbon atoms claim 12 , and{'sub': 1', '4', '1', '4', '2', '1', '4', '1', '4, 'where the linear hydrocarbyl chain can optionally be substituted by one or more substituents selected independently from the group consisting of C-Calkyl, N(H or C-Calkyl), OH, ═O, SH, ═S, F, Cl, Br, I, C-Calkoxy and C-Cmercapto, where alkyl is the same or different.'}14. The compound of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group consisting of alkylene claim 12 , alkenylene and alkynylene having 4 to 14 carbon atoms claim 12 ,where one or more carbon atoms in the linear hydrocarbyl chain are replaced by one or more heteroatoms selected from O, S and NH, and{'sub': 1', '4', '1', '4, 'where the linear hydrocarbyl chain can optionally be substituted by one or more substituents selected independently from the group consisting of OH, ═O, SH, ═S, C-Calkoxy and C-Cmercapto.'}15. The compound of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group consisting of alkylene claim 12 , alkenylene and alkynylene having 4 to 14 carbon atoms claim 12 ,where one or more carbon atoms in the linear hydrocarbyl chain are replaced by NH, and{'sub': 1', '4', '1', '4, 'where the linear hydrocarbyl chain can optionally be substituted by one or more substituents selected independently from the group consisting of OH, ═O, SH, ═S, C-Calkoxy and C-Cmercapto.'}16. The compound of claim 12 , wherein Z is a linear hydrocarbyl chain selected ...

IONIC LIQUID CONTAINING DIVALENT CATION AND MONOVALENT ANION AND LUBRICANT COMPOSITION COMPRISING SAME

Disclosed are an ionic liquid, having wear resistance maintained at low temperatures and containing a divalent cation including at least one of bis(ammonium) and bis(phosphonium) and a monovalent anion including at least one of sulfonate and phosphate, and a lubricant composition including the ionic liquid. 1. An ionic liquid , comprising:a divalent cation comprising at least one of bis(ammonium) and bis(phosphonium); anda monovalent anion comprising at least one of sulfonate and phosphate.3. The ionic liquid of claim 2 , wherein in Chemical Formula 1 claim 2 , Rand Rare each independently (C1-C20)alkyl claim 2 , (C2-C20)alkenyl claim 2 , (C2-C20)alkynyl claim 2 , (C3-C7)cycloalkyl claim 2 , (C5-C20)heteroalkyl claim 2 , (C6-C20)aryl claim 2 , (C6-C20)ar(C1-C10)alkyl claim 2 , (C1-C10)alkoxy claim 2 , (C6-C20)aryloxy claim 2 , (C1-C10)alkoxycarbonyl(C1-C20)alkyl claim 2 , or (C1-C20)alkylcarbonyl.4. The ionic liquid of claim 2 , wherein in Chemical Formula 1 claim 2 , Rand Rare each independently (C1-C8)alkyl claim 2 , and Ris (CH) claim 2 , where 1≤n≤12.6. The ionic liquid of claim 5 , wherein in Chemical Formula 2 claim 5 , Rand Rare each independently (C1-C20)alkyl claim 5 , (C2-C20)alkenyl claim 5 , (C2-C20)alkynyl claim 5 , (C3-C7)cycloalkyl claim 5 , (C5-C20)heteroalkyl claim 5 , (C6-C20)aryl claim 5 , (C6-C20)ar(C1-C10)alkyl claim 5 , (C1-C10)alkoxy claim 5 , (C6-C20)aryloxy claim 5 , (C1-C10)alkoxycarbonyl(C1-C20)alkyl claim 5 , or (C1-C20)alkylcarbonyl.7. The ionic liquid of claim 5 , wherein in Chemical Formula 2 claim 5 , Rand Rare each independently (C1-C8)alkyl claim 5 , and Ris (CH) claim 5 , where 1≤n≤12.10. The ionic liquid of claim 9 , wherein in Chemical Formula 6 claim 9 , Rand Rare each independently (C1-C20)alkyl claim 9 , (C2-C20)alkenyl claim 9 , (C2-C20)alkynyl claim 9 , (C3-C7)cycloalkyl claim 9 , (C5-C20)heteroalkyl claim 9 , (C6-C20)aryl claim 9 , (C6-C20)ar(C1-C10)alkyl claim 9 , (C1-C10)alkoxy claim 9 , (C6-C20)aryloxy claim 9 , (C1-C10) ...

ORGANIC ELECTROLUMINESCENT MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICES

The present application discloses an organic electroluminescent material, a molecular formula thereof is Da-π-Ac, wherein Da is an aggregation-induced emission group, π is a conjugated bond, and Ac is a strong electron-withdrawing group. The organic electroluminescent material of the present application has a simple preparation method, high yield, good thermodynamic stability, can cover the visible region, have excellent electroluminescence effect, and can prepare undoped type of organic electroluminescent devices. 5. An organic electroluminescent material , in which a molecular formula of the organic electroluminescent material is Da-π-Ac , wherein Da is an aggregation-induced emission group , π is a conjugated bond , and Ac is a strong electron-withdrawing group.12. An organic electroluminescent device , which comprises: a substrate; and an anode , a hole transport layer , a light-emitting layer , an electron transport layer and a cathode sequentially disposed on the substrate; wherein a molecular formula of the light-emitting layer is Da-π-Ac , Da is an aggregation-induced emission group , π is a conjugated bond , and Ac is a strong electron-withdrawing group. The present application relates to a display technical field; especially to an organic electroluminescent material and a related organic electroluminescent device.With the development of scientific technology, people have made increasing demands on the display devices of contrast, color change, resolution, cost, energy consumption and quality. Due to various high energy consumption, high cost and other shortcomings, liquid crystal display devices have become increasingly difficult to meet the demands of people, while the organic electroluminescent technology obtains a great development, an organic Light-Emitting Diode (OLED) has advantages of self-luminescence, low-voltage DC drive, wide viewing angle, fast response, wide operating temperature range and flexible display, etc.; therefore, it has become a ...

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are chemical entities which are compounds of formula (I): 144.-. (canceled)46. The compound or pharmaceutically acceptable salt of claim 45 , wherein R is tert-butoxycarbonyl (Boc).47. The compound or pharmaceutically acceptable salt of claim 45 , wherein R is diphenylphosphine oxide (DPP).52. The method of claim 51 , wherein converting Compound 2 to [(1R claim 51 ,2S claim 51 ,4R)-4-{[5-({4-[(1R)-7-chloro-1 claim 51 ,2 claim 51 ,3 claim 51 ,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a claim 51 , or a pharmaceutically acceptable salt thereof comprises:removing R and the triisopropylsilyloxy (TIPS) groups to obtain [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a, or a pharmaceutically acceptable salt thereof.53. The method of claim 51 , wherein Compound 1 is reacted with Int-259 in the presence of a base.54. The method of claim 52 , wherein R is removed in the presence of an acid.55. The method of claim 52 , wherein the triisopropylsilyloxy (TIPS) group is removed in the presence of an acid.56. The method of claim 52 , wherein R and the triisopropylsilyloxy (TIPS) group are removed in separate steps.57. The method of claim 52 , wherein R and the triisopropylsilyloxy (TIPS) group are removed concurrently in one step.58. The method of claim 50 , wherein [(1R claim 50 ,2S claim 50 ,4R)-4-{[5-({4-[(1R)-7-chloro-1 claim 50 ,2 claim 50 ,3 claim 50 ,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate of formula I-263a claim 50 , or a pharmaceutically acceptable salt thereof claim 50 , is isolated by a process selected from the group consisting of crystallization claim 50 , filtration claim 50 , trituration claim 50 , evaporation claim 50 , chromatography claim 50 , and combinations ...

PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES

The present invention relates to a process for preparing substituted biphenylanilides of the formula (I) 2. Process according to claim 1 , wherein the compound (II) is selected from the group consisting of N-(2-bromo-4-fluorophenyl)acetamide claim 1 , N-(2-bromophenyl)acetamide claim 1 , N-(2-bromophenyl)-3-oxobutanamide claim 1 , N-(2-bromo-4-fluorophenyl)-3-oxobutanamide claim 1 , 2-bromo-N-(propan-2-ylidene)aniline claim 1 , 2-bromo-4-fluoro-N-(propan-2-ylidene)aniline claim 1 , 2-bromo-4-fluoroaniline claim 1 , 2-bromoaniline.3. Process according to claim 1 , wherein the compound of the formula (III) is selected from the group consisting of bis(3 claim 1 ,4-dichlorophenyl)borinic acid claim 1 , bis(2 claim 1 ,3-dichlorophenyl)borinic acid claim 1 , bis(3-dichlorophenyl)borinic acid claim 1 , bis(4-dichlorophenyl)borinic acid claim 1 , 4-chlorophenylboronic acid claim 1 , 3-chlorophenylboronic acid claim 1 , 2-chlorophenylboronic acid claim 1 , 3 claim 1 ,4-dichlorophenylboronic acid and 2 claim 1 ,3-dichlorophenylboronic acid.4. Process according to claim 1 , wherein the base is selected from alkali metal hydroxides claim 1 , alkali metal carbonates and alkali metal hydrogencarbonates.5. Process according to claim 1 , wherein the palladium catalyst a) is a complex of palladium in the 0 oxidation state and a phosphine ligand of the formula (V) or a salt thereof.6. Process according to claim 1 , wherein a palladium catalyst b) is used.7. Process according to claim 1 , wherein a palladium catalyst c) is used claim 1 , and this palladium catalyst c) comprises or consists of metallic palladium on activated carbon in the presence of a phosphine ligand of formula (V) or a salt thereof.8. Process according to claim 6 , wherein the salt of the palladium catalyst b) is selected from the group consisting of palladium chloride claim 6 , palladium acetate claim 6 , palladium acetylacetonate and bis(acetonitrile)palladium chloride.9. Process according to claim 1 , wherein the ...

Cyclopentylacrylamide derivative

A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein R 1 and R 2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, or a C 1 to C 6 alkoxy-C 1 to C 6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).

METHOD FOR PRODUCING CATALYST FOR CYCLIC CARBONATE SYNTHESIS

The present invention provides a method for easily and inexpensively producing a heterogeneous catalyst used to synthesize a cyclic carbonate by reacting an epoxide with carbon dioxide and having excellent catalyst activity; a catalyst obtained using said manufacturing method; and a method for synthesizing a cyclic carbonate using said catalyst. 1. A method for producing a catalyst used to synthesize a cyclic carbonate by reacting an epoxide with carbon dioxide , comprising (a) and (b):(a) obtaining a catalyst precursor having a haloalkyl group or a haloaryl group by reacting a silane compound with a silica gel in the presence of xylene, wherein the silane compound having has a haloalkyl group or a haloaryl group, and(b) obtaining a catalyst for synthesizing a cyclic carbonate by reacting the catalyst precursor obtained in (a) with a tertiary phosphine.2. The method according to claim 1 , wherein the amount of the silane compound having a haloalkyl group or an haloaryl group ranges from 0.01 to 0.1 mol per 1 mol of silica gel.3. The method according to claim 1 , wherein the reaction time in (a) ranges from 1 to 30 hours.4. The method according to claim 1 , wherein the reaction temperature in (a) ranges from 50 to 160° C.5. The method according to claim 1 , wherein (b) is carried out in a hydrocarbon solvent.6. The method according to claim 5 , wherein the hydrocarbon solvent is xylene.7. The method according to claim 1 , wherein the silica gel used in (a) contains an amount of adsorbed water of 1% by mass or less.8. A catalyst obtained by the method according to .9. A method for synthesizing a cyclic carbonate by reacting an epoxide with carbon dioxide in the presence of the catalyst according to .10. The method according to claim 9 , wherein the epoxide is one or more members selected from the group consisting of ethylene oxide and propylene oxide. The present invention relates to a method for producing a catalyst used to synthesize a cyclic carbonate, a catalyst ...

Conductive metal paste

The purpose of the present invention is to provide a conductive metal paste having improved conductivity without increasing the amount of a conductive filler to be added. The conductive metal paste contains a metal filler and less than 1 mass % of an ionic liquid, and does not contain carbon nanotubes.

HETEROATOMIC-BASED HOLE-TRANSPORT MATERIALS

Heteroatomic hole transport materials are provided. The hole transport materials include a non-carbon core: two, four, or eight aromatic groups covalently bound to the non-carbon core; a. terminal substituted diphenylamine end unit on each aromatic group: and optionally aromatic linker groups linking the aromatic groups and the substituted diphenylamine end units. In some embodiments the non-carbon core is non-carbon central atom such as Si, Ge, B, PSn or Pb. In other embodiments, the non-carbon core is a cubic silsesquioxane. Also provided are methods for making these materials. The materials are particularly useful as hole transport materials in perovskite solar cells. 2. The compound of wherein M is selected from the group consisting of Si claim 1 , Ge claim 1 , B and P.3. The compound of wherein M is Si.4. The compound of wherein Ris selected from the group consisting of phenylene and thiophene.5. (canceled)6. The compound of wherein two adjacent Rgroups are joined by bridging group Rto form a polycyclic aromatic group.7. The compound of wherein M is P and the counterion is selected from the group consisting of halide claim 1 , bistriflimide claim 1 , triflate claim 1 , hexafluorophosphate and combinations thereof.8. The compound of wherein M is B and the counterion is an alkali metal cation.9. The compound of wherein Ris selected from the group consisting of Cto Calkoxy and b is 1 or 2.10. The compound of wherein b is 1 and Ris selected from the group consisting of para-methoxy and ortho-methoxy.21. The compound of wherein Ris selected from the group consisting of phenylene and fluorenylidene.22. The compound of wherein Ris selected from the group consisting of 1 claim 21 ,4-phenylene and 2 claim 21 ,7-9H-fluorenylidene.23. A device comprising a cathode claim 21 , a hole transport layer claim 21 , a light absorbing material claim 21 , an electron transport layer and an anode claim 21 ,wherein the hole transport layer comprises a compound selected from the group ...

Gas Sorbent and Carbon Dioxide Separation and Recovery System and Method

A gas sorbent is characterized in that a gas sorbing material that undergoes a phase change from solid to liquid at time of gas sorption and also undergoes a phase change from liquid to solid at time of gas desorption is supported in a carrier and the sorbent keeps its solid-like outer shape before/after the phase changes of the gas sorbing material.

TRIALKYLPHOSPHONIUM IONIC LIQUIDS, METHODS OF MAKING, AND ALKYLATION PROCESSES USING TRIALKYLPHOSPHONIUM IONIC LIQUIDS

A trialkylphosphonium haloaluminate compound having a formula: 2. The process of wherein R claim 1 , R claim 1 , and Rare Cto Chydrocarbyl.3. The process of wherein R claim 1 , R claim 1 , and Rhave the same number of carbon atoms.4. The process of wherein R claim 1 , R claim 1 , and Rare identical.5. The process of wherein each of R claim 4 , R claim 4 , and Ris selected from the group consisting of methyl claim 4 , ethyl claim 4 , propyl claim 4 , butyl claim 4 , pentyl claim 4 , and hexyl.6. The process of wherein the trialkylphosphonium haloaluminate compound comprises tri-n-butylphosphonium AlCl— claim 5 , tri-isobutylphosphonium AlCl— claim 5 , or di-n-butyl-sec-butylphosphonium AlCl—.7. The process of wherein an initial kinematic viscosity of the trialkylphosphonium ionic liquid catalyst composition is less than about 70 cSt at 25° C.8. The process of wherein a molar ratio of aluminum to phosphorous in the ionic liquid catalyst composition is in the range of 1.8 to 2.2.10. The process of wherein the trialkylphosphonium ionic liquid catalyst composition further comprises a co-catalyst.11. The process of wherein the co-catalyst comprises a Brønsted acid selected from the group consisting of HCl claim 10 , HBr claim 10 , HI claim 10 , and mixtures thereof claim 10 , or a Brønsted acid precursor.12. The process of further comprising:separating the alkylate and unreacted isoparaffin feed from the trialkylphosphonium ionic liquid catalyst composition to form a hydrocarbon stream comprising the alkylate and the unreacted isoparaffin feed and an ionic liquid stream comprising the trialkylphosphonium ionic liquid catalyst composition;separating the hydrocarbon stream into an alkylate stream and an unreacted isoparaffin stream; andrecycling at least one of the unreacted isoparaffin stream and the ionic liquid stream.13. The process of further comprising:regenerating at least a portion of the trialkylphosphonium ionic liquid catalyst composition in the ionic liquid ...

QUATERNARY AMMONIUM ETIDRONATES

The present invention provides a quaternary ammonium etidronate compound (QAE) comprising a quaternary ammonium cation and an etidronate anion, having the Formula I. 2. The compound of claim 1 , wherein R1 claim 1 , R2 claim 1 , R3 or R4 when substituted comprises substituent groups selected from one or more of a F claim 1 , Br claim 1 , I claim 1 , Cl claim 1 , —OR′ claim 1 , —NR′R″ claim 1 , —CF claim 1 , —CN claim 1 , —NO claim 1 , —CR′ claim 1 , —SR′ claim 1 , —N claim 1 , —C(═O)NR′R″ claim 1 , —NR′C(O)R″ claim 1 , —O(CR′R″)rC(═O)R′ claim 1 , O(CR′R″)rNR′C(O)R′ claim 1 , —(CR′R″)rNR″SOR′ claim 1 , —OC(O)NR′R″ claim 1 , —NR′C(O)OR″ claim 1 , —SOR′ claim 1 , —SONR′R″ claim 1 , —NR′SOR″; or combinations thereof claim 1 , wherein R′ and R″ are individually hydrogen claim 1 , C-Calkyl claim 1 , cycloalkyl claim 1 , heterocyclyl claim 1 , aryl claim 1 , or arylalkyl claim 1 , and R is an integer from 1 to 6 claim 1 , or R′ and R″ together form a cyclic functionality.3. The compound of claim 1 , wherein R1 and R2 are each a substituted or unsubstituted C-Calkyl.4. The compound of claim 3 , wherein claim 3 , R1 and R2 are each a CH.5. The compound of claim 1 , wherein R3 and R4 are each a substituted or unsubstituted straight chain or branched C-Calkyl claim 1 , aryl claim 1 , alkylaryl/arylalkyl claim 1 , cycloalkyl claim 1 , (aromatic or non-aromatic) heterocyclyl claim 1 , alkenyl claim 1 , phenyl claim 1 , alkyl-substituted phenyl claim 1 , benzyl claim 1 , naphthylmethyl claim 1 , or ethylbenzyl group.6. The compound of claim 1 , wherein the quaternary ammonium cation claim 1 , comprises a C-Cdialkyldimethyl ammonium claim 1 , C-Cdialkylmethylpoly(oxyethyl) ammonium claim 1 , C-Calkylbenzyldimethyl ammonium claim 1 , C-Calkyltrimethylammonium claim 1 , C-Cdialkyldihydroxyethyl ammonium claim 1 , C-Cdialkylmethylhydroxyethyl ammonium claim 1 , or C-Calkylmethyldihydroxyethyl ammonium.7. The compound of claim 6 , wherein the quaternary ammonium cation comprises a N ...

PHOSPHONIUM COMPOUND, EPOXY RESIN COMPOSITION INCLUDING THE SAME AND SEMICONDUCTOR DEVICE PREPARED FROM THE SAME

A phosphonium compound, an epoxy resin composition, a method of preparing a phosphonium compound, and a semiconductor device encapsulated with the epoxy resin composition, the compound being represented by Formula 1: 2. The phosphonium compound as claimed in claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare each independently a substituted or unsubstituted Cto Caryl group.3. The phosphonium compound as claimed in claim 2 , wherein at least one of R claim 2 , R claim 2 , R claim 2 , and Ris substituted with a hydroxyl group.6. The phosphonium compound as claimed in claim 5 , wherein R claim 5 , R claim 5 , R claim 5 , and Rare each independently a substituted or unsubstituted Cto Caryl group.7. The phosphonium compound as claimed in claim 6 , wherein at least one of R claim 6 , R claim 6 , R claim 6 , and Ris substituted with a hydroxyl group.11. An epoxy resin composition claim 6 , comprising:an epoxy resin,a curing agent,inorganic filler, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a curing catalyst, wherein the curing catalyst includes the phosphonium compound as claimed in .'}12. The epoxy resin composition as claimed in claim 11 , wherein the epoxy resin includes at least one of bisphenol A epoxy resin claim 11 , bisphenol F epoxy resin claim 11 , phenol novolac epoxy resin claim 11 , tert-butyl catechol epoxy resin claim 11 , naphthalene epoxy resin claim 11 , glycidyl amine epoxy resin claim 11 , cresol novolac epoxy resin claim 11 , biphenyl epoxy resin claim 11 , linear aliphatic epoxy resin claim 11 , cycloaliphatic epoxy resin claim 11 , heterocyclic epoxy resin claim 11 , spiro ring-containing epoxy resin claim 11 , cyclohexane dimethanol epoxy resin claim 11 , trimethylol epoxy resin claim 11 , and halogenated epoxy resin.13. The epoxy resin composition as claimed in claim 11 , wherein the curing agent includes a phenol resin.14. The epoxy resin composition as claimed in claim 11 , wherein the curing agent includes at least one of ...

Membrane Separation of Ionic Liquid Solutions

A membrane separation process using a highly fluorinated polymer membrane that selectively permeates water of an aqueous ionic liquid solution to provide dry ionic liquid. Preferably the polymer is a polymer that includes polymerized perfluoro-2,2-dimethyl-1,3-dioxole (PDD). The process is also capable of removing small molecular compounds such as organic solvents that can be present in the solution. This membrane separation process is suitable for drying the aqueous ionic liquid byproduct from precipitating solutions of biomass dissolved in ionic liquid, and is thus instrumental to providing usable lignocellulosic products for energy consumption and other industrial uses in an environmentally benign manner. 1. A method of separating an ionic liquid from a mixture comprising the steps of (i) providing the mixture that comprises ionic liquid and a liquid component selected from the group consisting of water , a small molecular compound and a blend thereof , (ii) providing a separator having a membrane comprising a selectively permeable , nonporous layer comprising a highly fluorinated polymer , through which membrane the liquid component transfers preferentially relative to the ionic liquid , (iii) providing a feed of the mixture in which the liquid component is present at an initial concentration , (iv) permeating components of the feed through the membrane , thereby selectively removing the liquid component from the feed , and (v) recovering from the membrane separator a liquid retentate product comprising the liquid component at a final concentration substantially lower than the initial concentration.2. The method of in which the ionic liquid is a compound selected from the group consisting of 1-allyl-3-methylimidazolium bis(trifluoromethanesulfonate) claim 1 , 1-ethyl-3-methylimidazolium acetate claim 1 , 1-ethyl-3-methylimidazolium chloride claim 1 , 1-ethyl-3-methylimidazolium bromide claim 1 , 1-ethyl-3-methylimidazolium tetrafluoroborate claim 1 , 1-ethyl-3- ...

Low Symmetry Molecules And Phosphonium Salts, Methods Of Making And Devices Formed There From

Synthesis of molecules and salts is disclosed having low average symmetry and their use in many applications, including but not limited to: as electrolytes in electronic devices such as memory devices including static, permanent and dynamic random access memory, as electrolytes in energy storage devices such as batteries, electrochemical double layer capacitors (EDLCs) or supercapacitors or ultracapacitors, electrolytic capacitors, as electrolytes in dye-sensitized solar cells (DSSCs), as electrolytes in fuel cells, as a heat transfer medium, high temperature reaction and/or extraction media, among other applications. In particular, synthesis methods and processes to form molecules and salts having low average symmetry using mixed Grignard reagents are disclosed.

Pharmaceutical compounds

Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.

Photostable aie luminogens for specific mitochondrial imaging and its method of manufacturing thereof

AIE (aggregation-induced emission)-active TPE derivatives, TPE-TPP, TPE-MitoR and TPE-IQ are contemplated. These specific TPE derivatives are useful as fluorescent agents for mitochondrial imaging and as apoptosis inducers. Possessing high specificity to mitochondria, superior photostability and appreciable tolerance to microenvironment change, TPE derivatives are well-suited imaging agents for mitochondrial targeting and morphological change tracking. Because of their synthetic flexibility, TPE derivatives can be further modified as dual-functional probes for an array of applications such as sensing of ROS, metal ions, or pH change in mitochondria.

SILICON-CONTAINING SULFURIC ACID ESTER SALT

Provided is a silicon-containing sulfuric acid ester salt comprising a silicon-containing sulfuric acid ester anion represented by formula (1) and a cation selected from cations respectively represented by formulae (2) to (5). 2. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein Rto Rare methyl groups.3. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein n is 2 or 3.4. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein the cation is a quaternary ammonium ion represented by the formula (2).6. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein the cation is the quaternary phosphonium ion represented by the formula (3).7. The silicon-containing sulfuric acid ester salt according to claim 6 , wherein Rand Rhave different structures.8. The silicon-containing sulfuric acid ester salt according to claim 7 , wherein Ris an alkyl group having 2 to 8 carbon atoms claim 7 , and Ris an alkyl group having 10 to 20 carbon atoms.9. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein the cation is an imidazolium ion represented by the formula (4).10. The silicon-containing sulfuric acid ester salt according to claim 1 , wherein the cation is a pyridinium ion represented by the formula (5).11. An ionic liquid comprising the silicon-containing sulfuric acid ester salt according to .12. The ionic liquid according to claim 11 , wherein a melting point is 25° C. or lower. The present invention relates to a silicon-containing sulfuric acid ester salt.In recent years, along with rapid proliferation of mobile electronic devices such as digital cameras, smartphones, and tablets, increasing are the demand for power storage devices such as secondary batteries which are used as power sources of these devices and can be repeatedly used by charging, and the demand for the increase of their capacity and energy density.These power storage devices commonly ...

Phosphonium-ion tethered tetracycline drugs for treatment of cancer

This invention relates to compounds that are useful as cancer therapies. The compounds comprise derivatives of tetracycline antibiotics, e.g. doxycycline, having a phosphonium cation tethered to the tetracycline tetracycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.

RESIN COMPOSITION, CURED PRODUCT THEREOF, FIBRE-REINFORCED PLASTIC, AND FIBRE-REINFORCED PLASTIC FLAMEPROOFING METHOD

Provided is a resin composition that is capable of producing a cured product having excellent environmental suitability, high strength, and excellent flame retardancy, and that is suitably usable as a matrix resin for fiber-reinforced plastics. A resin composition contains (A) an epoxy resin, (B) a cyanate resin, (C) an aromatic amine curing agent that is liquid at 25° C., and (D) a phosphorus-containing compound represented by formula (1). Preferably, in formula (1), Rand Reach independently represent an alkyl group or an aryl group, and X and Y are an oxygen atom. 2. The resin composition according to claim 1 , wherein Rand Reach independently represent an alkyl group or an aryl group claim 1 , and X and Y are each an oxygen atom.3. The resin composition according to claim 1 , wherein the hydrocarbon group represented by Rcontains at least one aromatic ring.5. The resin composition according to claim 1 , wherein the epoxy resin (A) contains from 20 to 80 mass % of a diglycidyl ether of bisphenol A-propylene oxide adduct.6. The resin composition according to claim 1 , wherein the phosphorus-containing compound (D) represented by formula (1) is contained in an amount that makes the content of phosphorus originating from the phosphorus-containing compound from 0.1 to 5 mass % with respect to a total solid content of the epoxy resin (A) claim 1 , the cyanate resin (B) claim 1 , the aromatic amine curing agent (C) that is liquid at 25° C. claim 1 , and the phosphorus-containing compound (D) represented by formula (1).7. A cured product obtained by curing the resin composition according to .8. A fiber-reinforced plastic obtained by curing a fiber-reinforced plastic composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the resin composition according to ; and'}a reinforcement fiber.9. A method for flame-proofing a fiber-reinforced plastic claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'obtaining a fiber-reinforced plastic ...

LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME

Provided are a light-emitting device and an electronic apparatus including the same. The light-emitting device includes: a first electrode; a second electrode facing the first electrode; an interlayer located between the first electrode and the second electrode; and an electron transport capping layer located outside the second electrode, wherein the interlayer includes an emission layer and an electron transport region, one of the electron transport region and the electron transport capping layer includes a first compound represented by Formula 1, and the other one includes the first compound, a second compound represented by Formula 2, or a combination thereof, and the electron transport region further includes a metal dopant: 2. The light-emitting device of claim 1 , wherein the electron transport capping layer includes the first compound claim 1 , andthe electron transport region includes the second compound and the metal dopant.3. The light-emitting device of claim 1 , wherein the electron transport region includes an electron transport layer claim 1 , andthe electron transport layer includes the first compound, the second compound, or a combination thereof; and the metal dopant.4. The light-emitting device of claim 3 , wherein the electron transport layer includes the second compound and the metal dopant.5. The light-emitting device of claim 4 , wherein the metal dopant includes alkali metal claim 4 , alkaline earth metal claim 4 , rare earth metal claim 4 , or a combination thereof.6. The light-emitting device of claim 4 , wherein an amount of the metal dopant in the electron transport layer is 5 wt % or less.7. The light-emitting device of claim 3 , wherein the electron transport region further includes a hole-blocking layer claim 3 , an electron control layer claim 3 , an electron injection layer claim 3 , or any combination thereof.8. The light-emitting device of claim 3 , wherein the electron transport region consists of the electron transport layer.9. ...

Mito-honokiol compounds and methods of synthesis and use thereof

The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.

LUBRICANT INCLUDING SILICON-CONTAINING IONIC LIQUID

Provided is a lubricant including a silicon-containing ionic liquid represented by formula (1). 2. The lubricant of claim 1 , wherein Ris a linear alkyl group of 10 to 20 carbon atoms.3. The lubricant of claim 1 , wherein all Rgroups are n-butyl or n-hexyl groups.4. The lubricant of claim 1 , wherein all Rgroups are methyl groups.5. The lubricant of which consists solely of a silicon-containing ionic liquid of formula (1).6. The lubricant of claim 1 , further comprising at least one additive selected from the group consisting of surfactants claim 1 , dispersants claim 1 , antioxidants claim 1 , anti-wear agents claim 1 , rust inhibitors claim 1 , corrosion inhibitors claim 1 , friction modifiers claim 1 , extreme pressure additives claim 1 , antifoam agents claim 1 , viscosity modifiers and pour point depressants.7. The lubricant of claim 6 , wherein the additive is a friction modifier or au anti-wear agent.10. The lubricant of claim 2 , wherein all Rgroups are n-butyl or n-hexyl groups.11. The lubricant of claim 2 , wherein all Rgroups are ethyl groups.12. The lubricant of claim 3 , wherein all Rgroups are methyl groups.13. The lubricant of which consists solely of a silicon-containing ionic liquid of formula (1).14. The lubricant of which consists solely of a silicon-containing ionic liquid of formula (1).15. The lubricant of which consists solely of a silicon-containing ionic liquid of formula (1).16. The lubricant of claim 2 , further comprising at least one additive selected from the group consisting of surfactants claim 2 , dispersants claim 2 , antioxidants claim 2 , anti-wear agents claim 2 , rust inhibitors claim 2 , corrosion inhibitors claim 2 , friction modifiers claim 2 , extreme pressure additives claim 2 , antifoam agents claim 2 , viscosity modifiers and pour point depressants.17. The lubricant of claim 3 , further comprising at least one additive selected from the group consisting of surfactants claim 3 , dispersants claim 3 , antioxidants claim 3 , ...

Friction and wear reduction additives

The present invention relates to additives for reducing friction and wear in lubricants. In particular, the present invention relates to novel salts and their use in lubricating oil compositions for reducing friction and wear. In particular, the present invention relates to one or more ionic liquids, wherein the one or more ionic liquids comprise one or more cations and one or more Group 6 metal mononuclear metallate anions.

Process for the generation of metallic films

The present invention is in the field of processes for the generation of thin inorganic films on substrates, in particular atomic layer deposition processes. It relates to a process for preparing metal films comprising (a) depositing a metal-containing compound from the gaseous state onto a solid substrate and (b) bringing the solid substrate with the deposited metal-containing compound in contact with a reducing agent in the gaseous state, wherein the reducing agent is or at least partially forms at the surface of the solid substrate a carbene, a silylene or a phosphor radical.

METHOD FOR TREATMENT OF SENESCENCE-RELATED DISORDERS

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammation, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia. 111-. (canceled)13. The method of claim 12 , wherein the at least one senescence-related disease or senescence-related health condition is selected from the group consisting of idiopathic pulmonary fibrosis claim 12 , sarcopenia claim 12 , diabetes claim 12 , obesity claim 12 , osteoarthritis claim 12 , chronic inflammations claim 12 , glaucoma claim 12 , cataracts claim 12 , radiation-induced oral mucosis claim 12 , renal transplantation claim 12 , prostatic hyperplasia and combinations thereof.14. The method of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group consisting of alkylene claim 12 , alkenylene and alkynylene having 4 to 14 carbon atoms claim 12 , and{'sub': 1', '4', '1', '4', '2', '1', '4', '1', '4, 'where the linear hydrocarbyl chain can optionally be substituted by one or more substituents selected independently from the group consisting of C-Calkyl, N(H or C-Calkyl), OH, ═O, SH, ═S, F, Cl, Br, I, C-Calkoxy and C-Cmercapto, where alkyl is the same or different.'}15. The method of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group consisting of alkylene claim 12 , alkenylene and alkynylene having 4 to 14 carbon atoms claim 12 ,where one or more carbon atoms in the linear hydrocarbyl chain are replaced by one or more heteroatoms selected from O, S and NH, and{'sub': 1', '4', '1', '4, 'where the linear hydrocarbyl chain can optionally be substituted by one or more substituents selected independently from the group consisting of OH, ═O, SH, ═S, C-Calkoxy and C-Cmercapto.'}16. The method of claim 12 , wherein Z is a linear hydrocarbyl chain selected from the group ...

COMPOUND CONTAINING PHOSPHONIUM ION, EPOXY RESIN COMPOSITION CONTAINING SAME, AND DEVICE MANUFACTURED BY USING SAME

The present invention relates to a compound containing phosphonium ion of a chemical formula 1, an epoxy resin composition containing the same, and a device manufactured by using the same. 3. The phosphonium ion-containing compound according to claim 1 , wherein Ris a substituted or unsubstituted Cto Calkyl group claim 1 , a substituted or unsubstituted Cto Cheteroaryl group claim 1 , or a compound represented by Formula 2 in which Ris a substituted or unsubstituted Cto Calkyl group or a substituted or unsubstituted Cto Caryl group.5. An epoxy resin composition claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an epoxy resin, a curing agent, and a curing catalyst, the curing catalyst including the phosphonium ion-containing compound according to .'}6. The epoxy resin composition according to claim 5 , wherein the epoxy resin includes an epoxy resin having two or more epoxy groups and one or more hydroxyl groups per molecule.7. The epoxy resin composition according to claim 5 , wherein the epoxy resin includes one or more of a bisphenol epoxy resin claim 5 , a phenol novolac epoxy resin claim 5 , a tert-butyl catechol epoxy resin claim 5 , a naphthalene epoxy resin claim 5 , a glycidyl amine epoxy resin claim 5 , a phenol aralkyl epoxy resin claim 5 , a cresol novolac epoxy resin claim 5 , a biphenyl epoxy resin claim 5 , a linear aliphatic epoxy resin claim 5 , an alicyclic epoxy resin claim 5 , a heterocyclic epoxy resin claim 5 , a spiro ring-containing epoxy resin claim 5 , a cyclohexane dimethanol epoxy resin claim 5 , or a halogenated epoxy resin.8. The epoxy resin composition according to claim 5 , wherein the curing agent includes a phenol resin.9. The epoxy resin composition according to claim 5 , wherein the curing agent includes one or more of a phenolaralkyl phenol resin claim 5 , a phenol novolac phenol resin claim 5 , a xyloc phenol resin claim 5 , a cresol novolac phenol resin claim 5 , a naphthol phenol resin claim 5 , a terpene ...

HETEROCYCLIC SELENAPHOSPHITES AND PROCESS FOR PREPARATION THEREOF

Novel heterocyclic selenaphosphites, process for preparation thereof and use thereof as ligand for employment in complexes. 5. Compound according to claim 1 , characterized in that in the heterocyclic selenaphosphite of the general structure (I){'sup': 2', '3', '4', '5', '6', '7', '8', '9, 'sub': 1', '12', '1', '12, 'R, R, R, R, R, R, Rand Rare each independently selected from: —H, -(C-C)-alkyl, —O-(C-C)-alkyl, and'}{'sup': '1', '—Rin the heterocyclic selenaphosphite of the general structure (I) is independently selected from the structures (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) and (X)'}where the radicals{'sup': 10', '11', '12', '13', '14, 'R, R, R, R, Rin the structure (II),'}{'sup': 15', '16', '17', '18', '19', '20', '21', '22, 'R, R, R, R, R, R, Rand Rin structure (III),'}{'sup': 24', '25', '26', '27', '28', '29', '30', '31', '32', '33, 'R, R, R, R, R, R, R, R, Rand Rin structure (IV),'}{'sup': 35', '36', '37', '38', '39', '40', '41', '42', '43', '44, 'R, R, R, R, R, R, R, R, Rand Rin structure (V),'}{'sup': 46', '47', '48', '49', '50', '51', '52', '53', '54', '55', '56', '57, 'R, R, R, R, R, R, R, R, R, R, Rand Rin structure (VI),'}{'sup': 59', '60', '61', '62', '63', '64', '65, 'R, R, R, R, R, Rand Rin structure (VII), and'}{'sup': 66', '67', '68', '69', '70', '71', '72', '73', '74, 'R, R, R, R, R, R, R, Rand Rin structure (VIII),'}{'sub': 1', '12', '1', '12', '1', '12', '1', '12', '1', '12', '6', '20', '1', '12', '1', '12, 'sup': 23', '34', '45', '58, 'in each structure are each independently selected from: —H, -(C-C)-alkyl, —O-(C-C)-alkyl, and where in each case independently, in addition to the aforementioned groups in the structures (III), (IV), (V) and (VI), R, R, R, Rare each independently selected from —H and —O—X with X=protecting group, where the protecting group X is selected from -(C-C)-alkyl, -(C-C)-alkyl-O-(C-C)-alkyl, -(C-C)-aryl-O-(C-C)-alkyl, —COO-(C-C)-alkyl.'}9. Process according to claim 6 , wherein (i) the reaction is effected in ...

METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS

A two-step pathway for preparing high pure quaternary phosphonium salts is disclosed. In the first step, hydrogen phosphide (PH) or a higher phophine reacts with a protonic compound to produce a phosphonium salt, which then reacts with a carbonic acid diester to produce a quaternary phosphonium salt in the second step. On one hand, hydrogen phosphide (PH) and higher phophines, including primary phosphines, secondary phosphines, and tertiary phosphines, after neutralization with protonic compound, become sufficiently reactive and can be alkylated by carbonic acid diester to form quaternary phosphonium cations. On the other hand, as an anion-exchange procedure is completely avoided, the process not only gives quaternary phosphonium salts of high purity, but also gives people freedom to design the cation and the anion of a quaternary phosphonium salt synchronously by choosing a preferred phosphine and a protonic compound that can supply a desired anion. 1. A process for preparing a quaternary phosphonium salt comprising:(a) a first step of reacting hydrogen phosphide or a higher phophine with a protonic compound to produce a phosphonium salt, and(b) a second step of reacting the phosphonium salt obtained from the first step with a carbonic acid diester to produce a quaternary phosphonium salt.2. The process as claimed in claim 1 , wherein the phophine is selected from the group consisting of primary phosphines claim 1 , secondary phosphines and tertiary phosphines.3. The process as claimed in claim 2 , the phosphine is selected from the group consisting of methyl phosphine claim 2 , ethyl phospine claim 2 , n-propyl phosphine claim 2 , cyclohexyl phosphine claim 2 , phenyl phosphine claim 2 , dimethyl phosphine claim 2 , diethyl phosphine claim 2 , di-i-propyl phosphine claim 2 , diphenyl phosphine claim 2 , di-i-butyl phosphine claim 2 , dicyclohexyl phosphine claim 2 , diphenyl phosphine claim 2 , ethyl methyl phophine claim 2 , trimethyl phosphine claim 2 , triethyl ...

PROCESS FOR THE PREPARATION OF PERFLUOROALKYLCYANO- OR PERFLUOROALKYLCYANOFLUOROBORATES

The invention relates to a process for the preparation of salts having perfluoroalkyltricyano- or perfluoroalkylcyanofluoroborate anions, ((per)fluoro)phenyltricyano- or ((per)fluoro)phenylcyanofluoroborate anions, phenyltricyanoborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms or phenylcyanofluoroborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms, by reaction of alkali metal trifluoroperfluoroalkylborate with trialkylsilyl cyanide and a subsequent salt-exchange reaction or by direct reaction of an organic trifluoroperfluoroalkyl borate with trialkylsilyl cyanide. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. A salt of formula III{'br': None, 'sup': a+', '−, 'sub': f', 'x', 'y', 'a, 'M[B(R)(CN)(F)]\u2003\u2003III,'}where{'sup': 'a+', 'M is a lithium, potassium, sodium, caesium or rubidium salt,'}{'sub': f', '6', '5', '6', '5, 'Rdenotes a linear or branched perfluorinated alkyl group having 1 to 4 C atoms, CF, CH, partially fluorinated phenyl, or phenyl which is mono- or disubstituted by a perfluoroalkyl group having 1 to 4 C atoms, where the perfluoroalkyl group is selected independently of one another,'}a is 1,x is 1, 2 or 3,{'sub': f', '6', '5, 'y is 0, 1 or 2, where 0 is excluded for R═CH, and'}x+y is 3.11. A salt according to claim 10 , that is potassium trifluoromethyltricyanoborate claim 10 , potassium pentafluoroethyltricyanoborate claim 10 , potassium heptafluoropropyltricyanoborate claim 10 , potassium trifluoromethyldicyanofluoroborate claim 10 , potassium pentafluoroethyldicyanofluoroborate claim 10 , potassium heptafluoropropyldicyanofluoroborate claim 10 , potassium trifluoromethylmonocyanodifluoroborate claim 10 , potassium pentafluoromethylmonocyanodifluoroborate claim 10 , potassium heptafluoropropylmonocyanodifluoroborate claim 10 , potassium nonafluorobutylmonocyanodifluoroborate claim 10 ...

Method for producing arene compounds and arene compounds produced by the same

Provided is a method for producing (alkyl)arene compounds represented by Formulae 3-1, 3-2, and 3-3 by the Friedel-Crafts alkylation reaction of alkyl halide compounds and arene compounds using organic phosphine compounds as a catalyst.

A GOLD(III) COMPLEX, A CONJUGATE OF THE GOLD(III) COMPLEX, A PHARMACEUTICAL COMPOSITION COMPRISING THE GOLD(III) COMPLEX AND USES AND A PROCESS FOR PREPARING THE GOLD(III) COMPLEX

A gold(III) complex, a conjugate of the gold(iII) complex, a pharmaceutical composition comprising the gold(III) complex and uses and a process for preparing the gold(III) complex. The complex comprises a group of (ŜC)-cyclometallated gold(III) complexes containing a 1,1-dithio ligand, which exhibit antibacterial activity against multiresistant microorganisms or against biofilm activity or biofilm disruption. The gold(III) complex has efficacy against a variety of microorganisms and low toxicity. 2. The gold(III) complex of claim 1 , further including a complex with two type (I) structures connected by a piperazine ring.3. The gold(III) complex of claim 2 , further including homo and heterobinuclear complexes of type (I) claim 2 , wherein the Rhas coordination positions to another metal.4. The gold(III) complex of claim 1 , wherein Rincludes a phenyl; Rincludes an alkyl or a cycloalkyl; Rincludes an hydrogen; and Rincludes an aliphatic amine.5. The gold(III) complex of claim 4 , wherein the aliphatic amine includes NMe claim 4 , NEt claim 4 , N(CHPh) claim 4 , pyrrolidyl claim 4 , piperidinyl claim 4 , and azepanyl links claim 4 , or heterocyclical including piperazinyl or morpholinyl.6. A conjugate comprising the gold(III) complex of and at least one carrier claim 1 , preferably a pharmaceutical carrier.7. A pharmaceutical composition comprising the gold(III) complex of and at least one pharmaceutically acceptable excipient.8. The gold(III) complex of claim 1 , configured to be used as a medicament.9. The gold(III) complex of claim 1 , configured to be used as a medicament in the treatment and/or prevention of infections.10. The gold(III) complex of claim 1 , configured to be used as a medicament in the treatment and/or prevention of bacterial infections.11. The gold(III) complex of claim 1 , configured to be used as a medicament in the treatment and/or prevention of bacterial infections caused by multiresistant bacteria.12. The gold(III) complex of claim 1 , ...

STABLE MODIFIED POLYMER POLYOL DISPERSIONS

The present invention relates to new stable modified polymer polyol dispersions. The modified polymer polyols of the present invention comprise at least one polyol and a stable dispersion of polymeric particles in the at least one polyol. There are also disclosed processes for the preparation of the herein described modified polymer polyols, and processes for preparing polyurethane materials containing them. 2. The stable modified polymer polyol according to claim 1 , being obtainable by a process comprising the preparation of polymeric particles claim 1 , in the presence of the liquid polyol mixture claim 1 , by reaction of melamine, trimethylol melamine, the compound of formula (I), the compound of formula (II); and', 'mixtures thereof;', 'with, 'the at least one compound bearing at least one basic-nitrogen atom a.1) which is selected from'} I. [bis(hydroxymethyl)phosphanyl]methanol (THP) in a concentration selected from 0-99.9 mol %,', 'II. a tetrakis(hydroxymethyl) phosphonium salt (THPX) in a concentration selected from 0-50 mol %,', 'III. [bis(hydroxymethyl)phosphoryl]methanol (THPO) in a concentration selected from 0-99.9 mol %,', 'IV. {[bis(hydroxymethyl)phosphanyl]methoxy}methanol (mTHP) in a concentration selected from 0-80 mol %,', 'V. {bis[(hydroxymethoxy)methyl]phosphanyl}methanol (dTHP) in a concentration selected from 0-30 mol %,', 'VI. ({bis[(hydroxymethoxy)methyl]phosphanyl}methoxy)methanol (tTHP) in a concentration selected from 0-15 mol %,', 'VII. bis(hydroxymethyl)phosphorylmethoxymethanol (mTHPO) in a concentration selected from 0-20 mol %,', 'VIII. {bis[(hydroxymethoxy)methyl]phosphoryl}methanol (dTHPO) in a concentration selected from 0-10 mol %, and', 'being the sum total of phosphorus containing components of the mixture 100 mol %.', 'IX. ({bis[(hydroxymethoxy)methyl]phosphoryl}methoxy)methanol (tTHPO) in a concentration selected from 0-4 mol %;'}], 'the mixture of compounds bearing a phosphorus atom a.2) comprising'}3. The stable modified ...

Hydrochloric acid stripping process for ionic liquid regeneration process

A method for regenerating deactivated acidic ionic liquid is described. The method involves reducing a level of free hydrochloric acid in the deactivated acidic ionic liquid in a removal zone using at least one of heat, a stripping fluid, reduced pressure, and liquid-liquid extraction to form a deactivated acidic ionic liquid having a reduced level of free hydrochloric acid; and regenerating the deactivated acidic ionic liquid having the reduced level of free hydrochloric acid.

SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF

The present invention relates to the synthesis of ent-progesterone and intermediates thereof. This application is a continuation of International Patent Application No. PCT/US2014/030040, filed Mar. 15, 2014, and claims the benefit of and priority to U.S. Provisional Patent Application No. 61/790,366, filed Mar. 15, 2013, the contents of which are incorporated herein by reference in their entirety.The present invention relates to the synthesis of ent-progesterone and intermediates thereof.Progesterone is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species. Progesterone belongs to a class of hormones called progestogens, and is the major naturally occurring human progestogen.Progesterone is naturally produced by the ovaries of mammals, but may also be produced by some plants and yeast. An economical semi-synthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke-Davis pharmaceutical company [Marker R E, Krueger J (1940). “Sterols. CXII. Sapogenins. XLI. The Preparation of Trillin and its Conversion to Progesterone”. J. Am. Chem. Soc. 62 (12): 3349-3350]. This synthesis is known as the Marker degradation. Additional semi-syntheses of progesterone have also been reported starting from a variety of steroids. For the example, cortisone may be simultaneously deoxygenated at the C-17 and C-21 position by treatment with iodotrimethylsilane in chloroform to produce 11-keto-progesterone (ketogestin), which in turn may be reduced at position-11 to yield progesterone. [Numazawa M, Nagaoka M, Kunitama Y (September 1986). “Regiospecific deoxygenation of the dihydroxyacetone moiety at C-17 of corticoid steroids with iodotrimethylsilane”. Chem. Pharm. Bull. 34 (9): 3722-6].A total synthesis of progesterone was reported in 1971 by W. S. Johnson. [Johnson W S, Gravestock M B, McCarry B E (August 1971). “Acetylenic bond participation in biogenetic ...

METHOD OF PRODUCING L-GLUFOSINATE

Provided is a method for preparing L-glufosinate from an L-homoserine derivative compound, the method including a step (step a) of preparing a compound of Chemical Formula 2 from a compound of Chemical Formula 1, and a step (step b) of preparing a compound of Chemical Formula 3 from the compound of Chemical Formula 2. 5. The method for preparing L-glufosinate according to claim 1 , wherein the Ris acetyl or succinyl.6. The method for preparing L-glufosinate according to claim 1 , wherein the Ris any one selected from the group consisting of hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , butyl claim 1 , pentyl claim 1 , hexyl claim 1 , benzyl claim 1 , phenyl and naphthyl.7. The method for preparing L-glufosinate according to or claim 1 , wherein the Rand Rindependently of one another are selected from the group consisting of methyl claim 1 , ethyl claim 1 , propyl claim 1 , butyl claim 1 , pentyl and hexyl.8. The method for preparing L-glufosinate according to or claim 1 , wherein the compound of Chemical Formula 1 is prepared from a fermentation liquid containing the precursor of the compound of Chemical Formula 1.9. The method for preparing L-glufosinate according to or claim 1 , wherein the halogenating agent includes at least one selected from the group consisting of HCl claim 1 , HBr claim 1 , HI claim 1 , phosgene claim 1 , SOCl claim 1 , oxalyl chloride claim 1 , trimethylsilyl halide claim 1 , sodium iodide (NaI) claim 1 , triethylsilane claim 1 , (CHCH)SiH)+palladium chloride (PdCl)+methyl iodide(CHI) claim 1 , POCl claim 1 , PCl claim 1 , PCl claim 1 , PBr claim 1 , PI claim 1 , HSO+KBr claim 1 , P+Cl claim 1 , P+Br claim 1 , P+I claim 1 , TiCl claim 1 , ZnCland BBr.10. The method for preparing L-glufosinate according to or claim 1 , wherein the R—OH includes at least one selected from the group consisting of methanol claim 1 , ethanol claim 1 , n-propanol claim 1 , iso-propanol claim 1 , butanol claim 1 , pentanol claim 1 , hexanol ...

PROCESS FOR THE PREPARATION OF PHOSPHONIUM SULFONATES

The invention relates to a process for the preparation of phosphonium sulfonates, particularly tetraalkylphosphonium fluoroalkylsulfonates, in the presence of amine-type bases. 2. Process according to claim 1 , wherein R is a straight perfluoro alkyl group having 2 to 8 carbon atoms.3. Process according to claim 2 , wherein R is a nonafluorobutyl group.4. Process according to wherein R′ claim 2 , R″ claim 2 , R′″ and R″″ are a butyl group.5. Process according to claim 1 , wherein the amine-type base is selected from alkyl- claim 1 , dialkyl- and trialkylamine claim 1 , ethanolamine claim 1 , morpholine claim 1 , piperazine claim 1 , piperidine claim 1 , quinuclidine claim 1 , pyridine and aniline.6. Process according to claim 1 , wherein the amine-type base is selected from trimethylamine claim 1 , triethylamine claim 1 , tributylamine claim 1 , ammonium hydroxide and tetra-alkyl ammonium hydroxide.7. Process according to claim 1 , wherein X is Br.9. Process according to claim 1 , wherein the amine-type base is used in a molar amount at least twice the molar amount of the compounds of formula (II) or (III).10. Process according to claim 1 , wherein the reaction is carried out at a temperature comprised between room temperature and the reflux temperature of the reaction mixture.11. Process according to claim 1 , which comprises isolating the compound of formula (I) after washing it with water in the presence of an additive selected from non-ionic surfactants and acetone.12. Process according to claim 11 , characterized in that said additive is acetone.13. Process according to claim 12 , characterized in that said acetone is present at concentrations of 0.1-20% (w/w) with respect to the water used for washing.14. Process according to claim 13 , characterized in that said acetone is present at a concentration of 5% (w/w) with respect to the water used for washing. The present invention relates to a process for the preparation of phosphonium sulfonates, particularly ...

Ionic Tags for Synthesis of Oligoribonucleotides

The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein.

Ylide-functionalised phosphanes for use in metal complexes and homogeneous catalysis

The invention relates to ylide-functionalized phosphane ligands, the production of same and use in transition metal compounds, as well as the use of same as catalysts in organic reactions.

IONIC LIQUIDS COMPRISING HETERAROMATIC ANIONS

Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein. 2. The ionic liquid of claim 1 , wherein the reaction energy ΔH>−99 kJ/mol.3. The ionic liquid of claim 1 , wherein the anion-CObond energy ΔE<−35 kJ/mol.4. The ionic liquid of claim 1 , wherein Rand Rare H and Ris NO.6. The method of claim 5 , wherein the mixture of gases is an exhaust from combustion of a carbon-based fuel claim 5 , wherein the carbon-based fuel is coal claim 5 , a petroleum product claim 5 , or natural gas.7. The method of claim 5 , wherein the mixture of gases further comprises an oxide of sulfur or nitrogen.8. The method of further comprising recovering the carbon dioxide from the second ionic liquid by applying at least one of heat or reduced pressure to the second ionic liquid.10. The gas separation system of claim 5 , further comprising a regeneration component wherein the ionic liquid according to is subjected to heat and/or reduced pressure to liberate carbon dioxide.11. A combustion device comprising:a combustion vessel configured to contain a combustion reaction;an exhaust component, in fluid communication with the combustion vessel, which is configured to allow exhaust from the combustion reaction to escape from the combustion vessel, wherein the exhaust comprises carbon dioxide; and{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, 'the gas separation system of , coupled to the exhaust component;'}wherein the device is configured to provide sufficient contact between the exhaust and the separation system to remove at least a portion of the carbon dioxide from the exhaust. This application is a divisional of U.S. patent application Ser. No ...

CATIONIC PILLARARENES AND USES THEREOF

The present invention provides cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives, capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition; as well as compositions thereof and methods of use. 2. The compound of claim 1 , wherein:{'sub': 1', '6', '7', '6', '7', '2', '2', '2', '2', '3', '2', '1', '8', '2', '2', '2', '2', '3', '2', '3', '3', '1', '4, 'sup': +', '+, '(i) Ris —CRR—, wherein Rand Reach independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, or (C-C)alkyl optionally substituted by one or more groups each independently selected from the group consisting of —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, —N(R′)or —P(R′), wherein R′ each independently is H, (C-C)alkyl, phenyl, or benzyl; or'}{'sub': 2', '3', '1', '4', '2', '2', '2', '2', '3', '2', '3', '3', '1', '4, 'sup': '+', '(ii) Rand Reach independently is H, or (C-C)alkyl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, —N(R′)and —P(R′), wherein R′ each independently is H, (C-C)alkyl, phenyl, or benzyl; or'}{'sub': 4', '5', '2', '10', '2', '8', '2', '2', '2', '2', '3', '2', '6', '1', '4', '6', '1', '4', '1', '8', '6', '6, '(iii) Rand Reach independently is (C-C)alkylene or (C-C)alkylene, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, (C)aryl, (C-C)alkylene-(C)aryl, heteroaryl, and (C-C)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group each independently selected from the ...

Mitochondrially-Targeted Electrophilic Compounds and Methods of Use for the Treatment of Cancer

The present invention provides methods, compounds, compositions and kits including mitochondrially-targeted electrophilic (MTE) compounds that are useful for treating cancer. 1. A method of treating cancer , comprising administering to a subject an effective amount of a mitochondrially-targeted electrophilic (MTE) compound.2. The method of claim 1 , wherein the cancer is breast cancer claim 1 , osteosarcoma claim 1 , angiosarcoma claim 1 , fibrosarcoma claim 1 , leukemia claim 1 , lymphoma claim 1 , ovarian cancer claim 1 , uretal cancer claim 1 , bladder cancer claim 1 , prostate cancer claim 1 , genitourinary cancer claim 1 , colon cancer claim 1 , esophageal cancer claim 1 , stomach cancer claim 1 , gastrointestinal cancer claim 1 , lung cancer claim 1 , myelomas claim 1 , pancreatic cancer claim 1 , liver cancer claim 1 , kidney cancer; endocrine cancer claim 1 , skin cancer and brain cancer.3. The method of claim 1 , wherein the cancer is breast cancer.4. The method of claim 3 , wherein the cancer is triple negative.5. The method of claim 1 , wherein the cancer is treatment resistant.6. The method of claim 1 , wherein the MTE compound is radiolabeled.7. The method of claim 1 , wherein the MTE compound is iodobutyl triphenylphosphonium iodide (IBTP) or an analog thereof.9. The method of claim 1 , wherein the MTE compound is administered in combination with a chemotherapeutic agent.10. The method of claim 9 , wherein the MTE compound is administered prior to claim 9 , concurrently with claim 9 , or after administration of the chemotherapeutic agent.11. A method of preventing or reducing metastasis claim 9 , comprising administering to a subject an effective amount of a mitochondrially-targeted electrophilic (MTE) compound.13. The compound of claim 12 , wherein the compound is radiolabeled.14. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00012', 'claim 12'}, 'a compound of ; and'}a pharmaceutically acceptable carrier, excipient or diluent, ...

HYDROGEN SULFIDE RELEASING COMPOUNDS AND THEIR USE

The invention relates to a compound comprising a mitochondrial targeting group linked to group capable of releasing hydrogen sulfide, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by surgery or therapy. The invention also relates to the use of the compound in the treatment of a plant, and to certain forms of the compound. 1. A method for the treatment or prevention of a disease or disorder susceptible to amelioration by in vivo release of hydrogen sulphide , wherein the method comprises administering to a subject a compound comprising a mitochondrial targeting group linked to a group capable of releasing hydrogen sulfide , or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein the mitochondrial targeting group is a lipophilic cation selected from a phosphonium cation claim 1 , an arsonium cation claim 1 , an ammonium cation claim 1 , flupritine claim 1 , MKT-077 claim 1 , a pyridinium ceramide claim 1 , a quinolium claim 1 , a liposomal cation claim 1 , a sorbitol guanidine claim 1 , a cyclic guanidine or a rhodamine.3. The method of claim 1 , wherein the group capable of releasing hydrogen sulfide comprises a thiocarbamoyl group claim 1 , a 5-thioxo-5H-1 claim 1 ,2-dithiol-3-yl group claim 1 , a 5-thioxo-5H-1 claim 1 ,2-dithiol-4-yl group claim 1 , a 5-oxo-5H-1 claim 1 ,2-dithiol-3-yl group claim 1 , a 5-oxo-5H-1 claim 1 ,2-dithiol-4-yl group claim 1 , a 5-hydroxyimino-5H-1 claim 1 ,2-dithiol-3-yl group claim 1 , a 5-hydroxyimino-5H-1 claim 1 ,2-dithiol-4-yl group claim 1 , a phosphinodithioate group or a phosphinodithioic acid group.5. The method of claim 4 , wherein L is a linker represented by formula:{'br': None, '-L′-Y—Z—'} [{'sub': 1-20', '1-12', '1-12', '1-12', '1-12', '1-12, 'L′ represents a direct bond or a straight chain Calkylene group which is unsubstituted or substituted by one or more substituents selected from a halogen atom, hydroxy, Calkoxy, Calkyl, hydroxy-C-alkyl, ...

Nicotinamide mononucleotide derivatives and their uses

The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.

POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING CELLULOSIC MATERIALS USING SUCH CATALYSTS

Provided herein are catalysts useful in non-enzymatic saccharification processes. The catalysts can be polymeric catalysts or solid-supported catalysts with acidic and ionic moieties. Provided are also methods for hydrolyzing cellulosic materials into monosaccharides and/or oligosaccharides using the catalysts described herein. 1. A catalyst comprising a solid support , acidic moieties attached to the solid support , and ionic moieties attached to the solid support ,wherein the solid support comprises a material, wherein the material is selected from the group consisting of carbon, silica, silica gel, alumina, magnesia, titania, zirconia, clays, magnesium silicate, silicon carbide, zeolites, ceramics, and any combinations thereof,wherein each acidic moiety independently has at least one Bronsted-Lowry acid, andwherein each ionic moiety independently has at least one nitrogen-containing cationic group or at least one phosphorous-containing cationic group, or a combination thereof.2. The catalyst of claim 1 , wherein each Bronsted-Lowry acid is independently selected from the group consisting of sulfonic acid claim 1 , phosphonic acid claim 1 , acetic acid claim 1 , isophthalic acid claim 1 , boronic acid claim 1 , and perfluorinated acid.3. The catalyst of claim 1 , wherein one or more of the acidic moieties are directly attached to the solid support.4. The catalyst of claim 1 , wherein one or more of the acidic moieties are attached to the solid support by a linker.5. The catalyst of claim 1 , wherein each ionic moiety is selected from the group consisting of pyrrolium claim 1 , imidazolium claim 1 , pyrazolium claim 1 , oxazolium claim 1 , thiazolium claim 1 , pyridinium claim 1 , pyrimidinium claim 1 , pyrazinium claim 1 , pyradizimium claim 1 , thiazinium claim 1 , morpholinium claim 1 , piperidinium claim 1 , piperizinium claim 1 , pyrollizinium claim 1 , phosphonium claim 1 , trimethyl phosphonium claim 1 , triethyl phosphonium claim 1 , tripropyl phosphonium ...

IONIC LIQUID

An ionic liquid characterized by comprising a phosphonium salt represented by formula (1), which has such characteristic properties that no halogen atom is contained, thermal stability is excellent and hydrophobicity is exerted. 2. The ionic liquid of claim 1 , wherein Ris a straight-chain alkyl group of 10 to 20 carbons.3. The ionic liquid of claim 1 , wherein Ris n-butyl.4. The ionic liquid of claims 1 , wherein Ris methyl.5. The ionic liquid of claim 1 , wherein n is 3.6. The ionic liquid of claim 2 , wherein Ris n-butyl.7. The ionic liquid of claims 2 , wherein Ris methyl.8. The ionic liquid of claims 3 , wherein Ris methyl.9. The ionic liquid of claim 2 , wherein n is 3.10. The ionic liquid of claim 3 , wherein n is 3.11. The ionic liquid of claim 4 , wherein n is 3. The present invention relates to an ionic liquid. More specifically, the invention relates to an ionic liquid composed of tetraalkylphosphonium cations and trialkylsilyl group-containing alkylsulfonic acid anions.Most ionic liquids known to date contain halogen atoms such as fluorine atoms on the anions, and thus pose a problem in terms of their environmental impact. In addition, production costs are high. Improvements in these areas have been desired.In light of the above, ionic liquids of types that do not contain halogen atoms have also been developed (see, for example, Patent Documents 1 and 2). However, compared to ionic liquids which contain fluorine atoms, these have drawbacks such as a high viscosity and a low heat resistance (low decomposition point).In general, many ionic liquids exhibit hydrophilic properties, although such hydrophilicity itself is often a problem, as in cases where there is a desire to lower the water content and in cases where separation with water is required.Hence, ionic liquids possessing hydrophobicity to an extent such as to undergo phase separation with water have also been developed (see, for example, Patent Document 3). However, these ionic liquids include ...

BIOLOGICALLY ACTIVE COMPOUNDS SPECIFICALLY DELIVERED INTO MITOCHONDRIA

This invention relates to biology and medicine and, in particular, can be used in medicine to make a pharmaceutical composition for targeted delivery of biologically active substances into mitochondria, driven by proton electro-chemical potential in the mitochondria. This invention also relates to the method to affect an organism by the targeted delivery of biologically active compounds to mitochondria. The invention can be useful in treatment of diseases or disorders associated with not normal functioning of mitochondria, in particular diseases associated with increased production of free radicals and reactive oxygen species. 126-. (canceled) This invention relates to biology and medicine and, as an example of its application, provides a method of preparation of pharmaceutical compositions for targeted delivery of biologically active molecules into mitochondria, driven by proton electro-chemical potential. The invention also provides a method to treat an organism by said compounds delivered into mitochondria.Mitochondria play key roles in many vital processes of a living cell. The list of such processes includes energy conversion (since the principle function of mitochondria is to provide the cell with energy), metabolism of certain substances (e.g. fatty acids), etc. Mitochondria are also directly involved in production and utilization of free radicals (FR) and reactive oxygen species (ROS)—extremely active compounds that can affect many processes within a. living cell. Finally, mitochondria have been recently proved to play a key role in the process of programmed cell death.Many diseases are known to be related to the dysfunction of mitochondria. This includes all disorders connected to increased production of FR and ROS, single or mass dying of cells within a tissue of an organ, dysfunction of programmed cell death mechanism (apoptosis), dysfunction of fatty acid metabolism etc.It is assumed that by affecting mitochondria different aspects of functioning of the ...

Functionalized Ionic Liquids and Their Applications

Disclosure of functionalized ionic liquids. Use of disclosed ionic liquids as solvent for carbon dioxide. Use of disclosed ionic liquids as flame retardant. Use of disclosed ionic liquids for coating fabric to obtain flame retardant fabric. 2. A fire retardant coating for textile fabrics comprising the ionic liquid of .3. A solvent for carbon dioxide capture comprising the ionic liquid of .4. An electrolyte in a lithium ion battery comprising the ionic liquid of .5. A flame retardant additive to an electrolyte in a lithium ion battery comprising the ionic liquid of .6. An electrolyte in a metal air battery comprising the ionic liquid of .7. A flame retardant additive to an electrolyte in a metal air battery comprising the ionic liquid of .9. A fire retardant coating for textile fabrics comprising the ionic liquid of .10. A solvent for carbon dioxide capture comprising the ionic liquid of .11. An electrolyte in a lithium ion battery comprising the ionic liquid of .12. A. flame retardant additive to an electrolyte in a lithium ion battery comprising the ionic liquid of .13. An electrolyte in a metal air battery comprising the ionic liquid of .14. A flame retardant additive to an electrolyte in a metal air battery comprising the ionic liquid of .16. A fire retardant coating for textile fabrics comprising the ionic liquid of .18. An electrolyte in a lithium ion battery comprising the ionic liquid of .19. A flame retardant additive to an electrolyte in a lithium ion battery comprising the ionic liquid of .20. An electrolyte in a metal air battery comprising the ionic liquid of .21. A flame retardant additive to an electrolyte in a metal air battery comprising the ionic liquid of .24. A flame retardant fabric product comprising a fabric claim 15 , a flame retardant ionic liquid represented by Formula 3 claim 15 , and a binder.wherein about 1% to about 60% by weight of the flame retardant fabric product comprises the flame retardant ionic liquid,wherein the fabric is ...

USE OF DI-IONIC COMPOUNDS AS CORROSION INHIBITORS IN A WATER SYSTEM

Disclosed herein are the methods of using di-cationic or di-anionic compounds, which are derived from primary amine through an aza-Michael addition with an activated olefin, in a corrosion control composition to mitigate corrosion of a surface in a water system. The disclosed methods or compositions are found to be more effective than those methods or compositions including commonly used single quaternary compounds for mitigating corrosion for a metal surface in water systems. 2. (canceled)3. (canceled)4. The method according to claim 1 , wherein Ris Rand Ris a linear C-Calkyl claim 1 , alkenyl claim 1 , or alkynyl group.5. The method according to claim 1 , wherein Ris R—Z—(CH)— or R—Z(CH)— claim 1 , Z is NH claim 1 , and Ris a linear C-Calkyl claim 1 , alkenyl claim 1 , or alkynyl group.6. The method according to claim 1 , wherein Ris R—Z—(CH)— claim 1 , Z is O claim 1 , and Ris a linear C-Calkyl claim 1 , alkenyl claim 1 , or alkynyl group.7. (canceled)8. (canceled)9. (canceled)10. The method according to claim 1 , wherein Ris a C-Calkenyl group with at least one trans or cis double bond.11. The method according to claim 1 , wherein the corrosion control composition agent is a carrier claim 1 , wherein the carrier is water claim 1 , an organic solvent claim 1 , or a mixture thereof.12. The method according to claim 1 , wherein the corrosion control composition agent is a carrier and one or more additional corrosion inhibitors.13. The method according to claim 1 , wherein the corrosion control composition agent is a biocide claim 1 , wherein the biocide is chlorine claim 1 , hypochlorite claim 1 , ClO claim 1 , bromine claim 1 , ozone claim 1 , hydrogen peroxide claim 1 , peracetic acid claim 1 , peroxycarboxylic acid composition claim 1 , peroxysulphate claim 1 , glutaraldehyde claim 1 , dibromonitrilopropionamide claim 1 , isothiazolone claim 1 , terbutylazine claim 1 , polymeric biguanide claim 1 , methylene bisthiocyanate claim 1 , tetrakis hydroxymethyl ...

METHOD OF INCREASING MASS TRANSFER RATE OF ACID GAS SCRUBBING SOLVENTS

A method of increasing the overall mass transfer rate of acid gas scrubbing solids is disclosed. Various catalyst compounds for that purpose are also disclosed. 9. The method of wherein said acid gas scrubbing solvent includes an amine.10. The method of claim 1 , wherein said acid gas scrubbing solvent includes a mixture of a primary or secondary amine and a tertiary amine.11. The method of claim 1 , wherein said acid gas scrubbing solvent includes a material selected from a group consisting of monoethanolamine (MEA) claim 1 , 1-amino-2-propanol (1A2P) claim 1 , 3-amino-1-propanol claim 1 , 2-amino-1-propanol claim 1 , 2-amino-1-butanol claim 1 , 1-amino-2-butanol claim 1 , 3-amino-2-butanol claim 1 , 2-(alkylamino)ethanonol (MAE) claim 1 , diglycolamine claim 1 , morpholine claim 1 , piperazine (PZ) claim 1 , 1-methylpiperazine (NMP) claim 1 , 2-methylpiperazine claim 1 , hydroxypiperadine claim 1 , hydroxyalkylpiperazine claim 1 , 2-piperidineethanol claim 1 , N-aminoethylpierazine (AEP) claim 1 , aminopropylmorpholine claim 1 , 4-aminopiperidine claim 1 , 3-aminopiperidine claim 1 , 2-amino-piperidine claim 1 , diethanolamine claim 1 , 2-amino-2-methyl-1-propanol (AMP) claim 1 , diethanolamine (DEA) claim 1 , diisopropanolamine (DIPA) claim 1 , glycine claim 1 , alanine claim 1 , β-alannine claim 1 , sarcosine claim 1 , isopropanolamine claim 1 , benzylamine claim 1 , methyldiethanolamine (MDEA) claim 1 , triethanolamine (TEA) claim 1 , alkali carbonate claim 1 , N claim 1 ,N claim 1 ,-dialkylethanol amine claim 1 , N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraalky-1 claim 1 ,8-naphthalenediamine claim 1 , N claim 1 ,N claim 1 ,-dialkylbenzylamine claim 1 , 1 claim 1 ,4-dialkylpiperazine claim 1 , N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraalkyl-1 claim 1 ,6-hexanediamine claim 1 , N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraalkyl-1 claim 1 ,5-pentanediamine claim 1 , N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraalkyl-1 claim 1 ,4-butanediamine claim 1 , N claim 1 ,N ...

3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING

The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers. 7. The compound according to claim 6 , wherein the compound of interest is a biomolecule claim 6 , wherein the biomolecule is an antibody or a protein. This application is a divisional of U.S. application Ser. No. 14/899,883, filed Dec. 18, 2015, which is the National Stage of International Application No. PCT/EP2014/064387, filed on Jul. 4, 2014, which claims the benefit of European Application No. 13305950.1, filed Jul. 4, 2013. The contents of which are hereby incorporated by reference in their entirety.The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.Over 90% of the human proteins contain cysteines, while in silico digest of the human proteome revealed that only about 15% of all human tryptic peptides detectable by mass spectroscopy (MS) contain at least one cysteine in their sequence. This observation combined with the presence of a highly reactive thiol group on its side chain makes cysteine an attractive target for chemical labeling. Cysteine is the only coded amino acid that carries a nucleophilic sulfhydryl (or thiol) group (—SH), which largely exceeds the reactivity of any other nucleophilic function susceptible to be present in proteins. As a result, chemospecific cysteine derivatization is by far the most widely used method for chemical tagging of proteins. Among the vast number of chemical cysteine modification methods reported in literature so far, reagents such as N-substituted maleimides, 4-vinylpyridines and iodoacetamides are most commonly used. All of them possess drawbacks preventing them from being ideal methodology for ...

ANTI-CANCER AGENTS AND METHODS OF USE

An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands. 2. The anti-cancer agent of claim 1 , wherein Yis a substituted or unsubstituted indolyl.4. The anti-cancer agent of claim 3 , wherein the Au(I) is bound to the 5 carbon atom of the indolyl.5. The anti-cancer agent of wherein the sterically hindered phosphine ligand reduces the reactivity of the Au(I) with biological thiols and/or selenols when the anti-cancer agent is administered to a cancer cell.6. The anti-cancer agent of claim 5 , wherein the sterically hindered phosphine includes at least one substituted or unsubstituted C-Calkyl claim 5 , C-Calkenyl claim 5 , C-Calkynyl claim 5 , C-Caryl claim 5 , C-Calkaryl claim 5 , or C-Caralkyl bound to a phosphorous atom.7. The anti-cancer agent of claim 1 , wherein the sterically hindered phosphine comprises at least one of a triphenylphosphine claim 1 , tricyclohexylphosphine claim 1 , or dicyclobiphenylphosphine.8. The anti-cancer agent of selected from group consisting of 5-(triphenylphosphine-gold(I))-tert-butyl 1H-indole-1-carboxylate claim 1 , 5-(tricyclohexylphosphine-gold(I))-tert-butyl 1H-indole-1-carboxylate claim 1 , 5-[(1 claim 1 ,1′-biphenyl)-2-yldicyclohexylphosphine aurate(I)]-tert-butyl H-indole-1-carboxylate claim 1 , 5-[(1 claim 1 ,1′-biphenyl)-2-yldicyclohexylphosphine aurate(I)]-(1H indol-1-yl)methyl pivalate claim 1 , 5-[(1 claim 1 ,1′-biphenyl)-2-yldicyclohexylphosphine aurate(I)]-1-methyl-1H-indole claim 1 , and pharmaceutically acceptable salts thereof.9. The anti-cancer agent of claim 1 , being substantially unreactive with thioredoxin reductase.11. The method of claim 10 , wherein Yis a substituted or unsubstituted indolyl.13. The method of claim 12 , wherein the Au(I) is bound to the 5 carbon atom of the indolyl.14. The method of claim 10 , wherein the sterically hindered phosphine ligand reduces the reactivity of the Au(I) with biological thiols and/or selenols ...

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are chemical entities which are compounds of formula (I): 2. The chemical entity of claim 1 , wherein:{'sub': '2', 'claim-text': (i) a 5-membered heteroaryl or a 6-membered aryl or heteroaryl to form a bicyclic group; or', {'sub': 1-4', '1-4', '1-4', '1-4', '1-4', '1-4', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'sup': z7', 'z8', 'z8', 'z8', 'z7', 'z7', 'z7', 'z7', 'z7', 'z8', 'z7', 'z8', 'z7', 'z8', 'z9, '(ii) a 9-membered heteroaryl or a 10-membered aryl or heteroaryl to form a tricyclic group; wherein the ring system is optionally substituted by 1-3 independent occurrences of halogen, hydroxyl, cyano, Caliphatic, Cfluoroaliphatic, Calkoxy, Cfluoroalkoxy, —S—Caliphatic, —S—Cfluoroaliphatic, —N(R), —C(O)R, —S(O)R, —S(O)R, —C(O)R, —C(O)N(R), —S(O)N(R), —OC(O)N(R), —N(R)C(O)R, —N(R)SOR, —N(R)C(O)OR, T-R, a 5- to 6-membered heteroaryl, a 6-membered aryl, a 3- to 6-membered cycloaliphatic, or a 4- to 6-membered heterocyclyl; and the ring system is optionally substituted at one saturated carbon with oxo, a spirocyclic 3- to 6-membered carbocycle, or a spirocyclic 4- to 6-membered heterocycle;'}], '(a) Zis a ring system having a 5- to 7-membered heterocyclyl with 1-2 heteroatoms or a 5- to 7-membered cycloaliphatic fused to'}{'sup': 'z7', 'sub': '1-4', 'each occurrence of Ris independently hydrogen or Calkyl;'}{'sup': 'z8', 'sub': '1-4', 'each occurrence of Ris independently Calkyl;'}{'sub': 2', '1-2, 'Tis a Calkylene chain;'}{'sup': z9', 'z7', 'z7', 'z8', 'z7', 'z7, 'sub': 2', '2', '2, 'claim-text': OR', {'sub': '2', 'sup': 'e', 'claim-text': {'sup': 'e', 'sub': 3', '1-4', '1-4, '(i) Ris hydrogen, hydroxyl, halogen, —CF, or Caliphatic optionally substituted with one or more hydroxyl, halogen, or Caliphatic,'}, '(b) Zis L-Rwherein either, {'sup': e', 'f', 'f′, 'claim-text': {'sup': e', 'e', 'z7', 'z8', 'z8', 'z8', 'z7', 'z7', 'z7', 'z7', 'z7', 'z8', 'z7', 'z8', 'z7', 'z8', 'z9, 'sub': 1-4', '1-4', '1-4', '1-4', '1-4', '1-4', '2', '2', '2', '2', '2', '2', '2', ...

PHARMACEUTICAL COMPOUNDS

Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders. 3. A pharmaceutical formulation comprising a therapeutically-effective amount of at least one alkyl fatty acid analog or derivative of and at least one pharmaceutically-acceptable carrier or excipient therefor.4. The pharmaceutical formulation of claim 3 , wherein the at least one alkyl fatty acid analog or derivative is present in an amount to provide from about 0.001 mg/mto about 10 g/m.5. A method of treating claim 1 , preventing claim 1 , imaging claim 1 , or diagnosing a disease characterized by diseased cells or tissues that are sensitive to alkyl fatty acid analogs or derivatives comprising administering to a patient in need thereof a therapeutically-effective amount of at least one alkyl fatty acid analog or derivative according to .6. The method of claim 5 , wherein the at least one alkyl fatty acid analog or derivative is in a pharmaceutical formulation further comprising at least one pharmaceutically-acceptable additive. This invention relates to pharmaceutical agents, and more particularly to therapeutic agents comprising novel analogs and derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutically-acceptable formulations and methods of use therefor.The precise mechanism by which cancer arises continues to be the subject of intense investigation, and thus a unifying theory of the origin of cancer remains elusive. Recent research has confirmed that cancer is a disease arising from a patient's own cells and tissue. Indeed, it is now known that an individual patient may possess multiple tumor cell types, which may not be the same across patients with the same diagnosis or even in the same ...

CYANOTRIAZOLE COMPOUNDS

This invention relates to a cyanotriazole compound represented by the formula (1): 2. The compound or salt according to claim 1 , wherein Ris a group represented by formula:{'br': None, '-A-L1-B'} 'A is a divalent group selected from (A1) to (A45):', 'wherein'}(A1) a phenylene group,(A2) a thiazolediyl group,(A3) an oxazolediyl group,(A4) a thiophenediyl group,(A5) a furandiyl group,(A6) a pyrrolediyl group,(A7) a pyridinediyl group,(A8) a piperidinediyl group,(A9) an indolediyl group,(A10) a benzofurandiyl group,(A11) a benzothiophenediyl group,(A12)-lower alkylene-phenylene-,(A13) a pyrimidinediyl group,(A14) a quinolinediyl group,(A15) a 2,3-dihydroindolediyl group,(A16) an imidazolediyl group,(A17) a benzothiazolediyl group,(A18) an isoxazolediyl group,(A19) a 2,3-dihydrobenzofurandiyl group,(A20) an isothiazolediyl group,(A21) a dibenzofurandiyl group,(A22) a benzo[1,3]dioxolediyl group,(A23) a carbazolediyl group,(A24) a naphthalenediyl group,(A25) a 2-oxo-1,2,3,4-tetrahydroquinolinediyl group,(A26) a 6-oxo-1,6-dihydropyrimidinediyl group,(A27) an imidazo[1,2-a]pyridinediyl group,(A28) a [1,3,4]oxadiazolediyl group,(A29) a [1,2,4]thiadiazolediyl group,(A30) a benzoxazolediyl group,(A31) a [1,3,4]thiadiazolediyl group,(A32) a styrenediyl group,(A33) —CO-phenylene-,(A34) a cycloalkanediyl group,(A35) a higher alkylene group,(A36) a 2-oxo-1,2-dihydroquinolinediyl group,(A37) a benzimidazolediyl group,(A38) a 2,3-dihydro[1,4]benzodioxinediyl group,(A39) a fluorenediyl group,(A40) a bicyclo[2,2,1]hept-2-enediyl group,(A41) a thieno[3,2-b]pyridinediyl group,(A42) an imidazo[1,2-a]benzimidazolediyl group,(A43) a 3,4-dihydro-2H-[1,4]benzoxazinediyl group,(A44) a 3,4-dihydro-2H-benzo[b][1,4]dioxepinediyl group, and(A45) —NH—,each of (A1) to (A45) is optionally substituted with one or more members selected from the group consisting ofa halogen atom;a lower alkyl group optionally substituted with one or more halogen atoms;a lower alkenyl group;a hydroxy group;a lower ...

AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS

This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and the pharmaceutical formulations comprising said compounds. 3. A compound of claim 2 , wherein Lis selected from —C(O)— and —S(O)—.4. A compound of claim 2 , wherein Lis absent.5. A compound of any one of to claim 2 , wherein Ris H and Ris H.6. A compound of any one of to claim 2 , wherein Rand Rtogether form C(O).8. A compound of claim 7 , wherein Lis —C(O)—.9. A compound of claim 7 , wherein Lis —C(O)NR—.10. A compound of any one of to claim 7 , wherein Ris H.11. A compound of any one of to claim 7 , wherein Lis at each occurrence absent.12. A compound of any one of to claim 7 , wherein L claim 7 , L claim 7 , L claim 7 , L claim 7 , Land n are selected such that length of the linker formed by those groups is from 8 to 14 atoms.14. A compound of any one of to claim 7 , wherein Ris methyl and Ris methyl.15. A compound of any one of to claim 7 , wherein Ris H and Ris H.16. A compound of any one of to claim 7 , wherein Ris H and Ris C(O)CH.17. A compound of any one of to claim 7 , wherein R claim 7 , Rand Rare each substituted phenyl.18. A compound of any one of to claim 7 , wherein R claim 7 , Rand Rare each Cto C-cycloalkyl.19. A compound of any one of to claim 7 , wherein R claim 7 , Rand Rare each benzyl.20. A compound of any one of to claim 7 , wherein Rand Rare each unsubstituted phenyl and Ris independently selected from: substituted phenyl claim 7 , biphenyl claim 7 , naphthyl claim 7 , 5- claim 7 , 6- claim 7 , 9- or 10-membered heteroaryl claim 7 , Cto C-cycloalkyl claim 7 , C-C-alkyl and 4- to 8-membered heterocycloalkyl.21. A compound of any one of to claim 7 , wherein Rand Rare each Cto C-cycloalkyl and Ris independently selected from: phenyl claim 7 , biphenyl claim 7 , naphthyl claim 7 , 5- claim 7 , 6 ...

COMPOSITIONS AND METHODS FOR IMPROVING POLYMER FLOW RATE

The present disclosure provides a polymeric composition including a thermoplastic polymer and an ionic liquid compound, wherein the ionic liquid compound improves the melt flow rate of the polymeric composition. The present disclosure also provides a method of preparing a polymeric composition with improved melt flow rate by mixing an ionic liquid compound with a thermoplastic polymer to obtain the polymeric composition. 2. The method of claim 1 , wherein the thermoplastic polymer is selected from the group consisting of polycarbonates claim 1 , polyolefins claim 1 , polyimides claim 1 , polyphthalamide claim 1 , polyamides claim 1 , polymethyl methacrylate claim 1 , polyamideimides claim 1 , polysulfones claim 1 , polyethersulfones claim 1 , polyurethane claim 1 , polyarylsulfones claim 1 , poly ketones claim 1 , polyphenylsulfones claim 1 , polyetherimides claim 1 , polyetherketones claim 1 , polyphenylene sulfoxide claim 1 , thermoplastic vulcanizate and combinations thereof.3. The method of claim 1 , wherein the thermoplastic polymer is selected from the group consisting of rubber claim 1 , fiber claim 1 , plastic claim 1 , adhesive polymer claim 1 , polymer paint claim 1 , polymer composite claim 1 , engineering plastics claim 1 , thermoplastic elastomers claim 1 , and high temperature plastics.4. The method of claim 1 , wherein the thermoplastic polymer is selected from the group consisting of engineering plastics claim 1 , thermoplastic elastomers claim 1 , and high temperature plastics.5. The method of claim 1 , wherein the thermoplastic polymer is a high temperature polymer selected from the group consisting of polyamides claim 1 , polyamideimides claim 1 , polysulfones claim 1 , polyethersulfones claim 1 , polyarylsulfones claim 1 , poly ketones claim 1 , polyphenylsulfones claim 1 , polyetherimides claim 1 , polyetherketones claim 1 , polyphenylene sulfoxide claim 1 , and combinations thereof.6. The method of claim 1 , wherein the thermoplastic polymer is ...

MITO-MAGNOLOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF

The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers. 2. The mito-magnolol compound of claim 1 , wherein X is C-Calkyl claim 1 , each Y is H and R is H.10. A composition comprising the mito-magnolol compound of and a pharmaceutically acceptable carrier.11. A method of treating cancer in a subject having cancer comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering the mito-magnolol compound of in a therapeutically effective amount to treat the cancer.'}12. The method of claim 11 , wherein the cancer is melanoma.13. The method of claim 11 , wherein the cancer is resistant to anti-cancer therapy.14. The method of claim 13 , wherein the anti-cancer therapy is a BRAF inhibitor.15. The method of claim 13 , wherein the anti-cancer therapy is a checkpoint inhibitor.16. The method of claim 11 , wherein the mito-magnolol compound is administered in combination with one or more additional anti-cancer therapies.17. The method of claim 16 , wherein the anti-cancer therapy is a BRAF inhibitor.18. A method of reducing or inhibiting cancer cell growth in a subject having cancer claim 16 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering the mito-magnolol compound of in a therapeutically effective amount to reduce or inhibit cancer cell growth.'}19. The method of claim 18 , wherein the mito-magnolol compound is administered in combination with one or more anti-cancer therapies.20. A method of preventing or delaying resistance of a cancer to an anti-cancer therapy in a subject claim 18 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering the mito-magnolol compound of in a therapeutically effective amount to prevent or delay resistance of the cancer to the anti-cancer therapy.'}21. The method of claim 20 , wherein the ...

Ionic Liquid Preparation

A process for preparing a cationic species [Cat+] for an ionic liquid, said process comprising reacting a reagent (1) H 2 N-L-[Z] with a reagent (2) LG-L 2-EDG, to form a cationic species EDG-L 2-[Z+]-L-N(L 2-EDG) 2, wherein the process is carried out in a sealed reactor at a temperature of at least 100° C. 2. The process of claim 1 , wherein the process is carried out at a temperature of from 100 to 180° C. claim 1 , preferably from 115 to 170° C. claim 1 , and more preferably from 125 to 145° C.3. The process of or claim 1 , wherein the reaction is carried out for a period of from 0.5 to 24 hours claim 1 , preferably from 1 to 12 hours and more preferably from 2 to 6 hours.4. The process of any of to claim 1 , wherein the process is carried out at a pressure of from 105 to 500 kPa claim 1 , preferably from 200 to 400 kPa claim 1 , and more preferably from 250 to 350 kPa.5. The process of any of to claim 1 , wherein reagent (2) is used in an amount of from 1 to 6 molar equivalents claim 1 , preferably from 2 to 4 molar equivalents claim 1 , and more preferably from 2.5 to 3.5 molar equivalents as compared to reagent (1).6. The process of any of to claim 1 , wherein the reaction is carried out in the presence of a base claim 1 , preferably a nitrogen-containing base claim 1 , and more preferably a trialkylamine such as trimethylamine claim 1 , the base preferably being used in an amount of from 1 to 10 molar equivalents claim 1 , preferably from 2 to 8 molar equivalents claim 1 , and more preferably from 3 to 5 molar equivalents as compared to reagent (1).7. The process of any of to claim 1 , wherein the reaction is carried out in the presence of a protic solvent claim 1 , such as trichloromethane.8. The process of any of to claim 1 , wherein Lrepresents:{'sub': 1-10', '1-10, 'a linking group selected from Calkanediyl and Calkenediyl groups;'}{'sub': 1-6', '2-5, 'preferably a linking group selected from Calkanediyl and Calkenediyl groups;'}{'sub': '1-6', 'more ...

AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS

This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds. 3. A compound of claim 2 , wherein Lis selected from —C(O)— and —S(O)—.4. A compound of claim 2 , wherein Lis absent.5. A compound of any one of to claim 2 , wherein Ris H and Ris H.6. A compound of any one of to claim 2 , wherein Rand Rtogether form C(O).8. A compound of claim 7 , wherein Lis —C(O)—.9. A compound of claim 7 , wherein Lis —C(O)NR—.10. A compound of any one of to claim 7 , wherein Ris H.11. A compound of any one of to claim 7 , wherein Lis at each occurrence absent.12. A compound of any one of to claim 7 , wherein L claim 7 , L claim 7 , L claim 7 , L claim 7 , Land n are selected such that length of the linker formed by those groups is from 8 to 14 atoms.14. A compound of any one of to claim 7 , wherein Ris methyl and Ris methyl.15. A compound of any one of to claim 7 , wherein Ris H and Ris H.16. A compound of any one of to claim 7 , wherein Ris H and Ris C(O)CH.18. A compound of any one of to claim 7 , wherein the compound is for medical use.19. A compound of any one of to claim 7 , wherein the compound is for use in the treatment of cancer.20. A method for the treatment of cancer claim 7 , wherein the method comprises the administration of a therapeutically effective amount of a compound of any one of to .21. A pharmaceutical composition claim 7 , wherein the composition comprises a compound of any one of to and one or more pharmaceutically acceptable excipients. This invention relates to compounds that disrupt cell function, such as the disruption of cell metabolism in particular cancer cell metabolism, that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the ...